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ABSTRACT

Colorectal Cancer: Cost-Effectiveness of Screening and Chemoprevention in
Average Risk Males

Jarrett Coffindaffer

This study is an economic evaluation of currently recommended colorectal cancer
(CRC) screening procedures, and strategies that incorporate chemopreventive options
such as aspirin or a cycooxygenase-2 inhibitor. A decision analysis model was
constructed to compare alternative CRC screening strategies. A Markov model was
employed to simulate the natural history of CRC. Quality adjusted life years were used
as the primary outcome measure. The base case analysis represents the overall cost and
effectiveness associated with each screening strategy. Incremental cost-effectiveness
ratios (ICERs) were calculated for each screening strategy. One-way sensitivity analyses
were performed to assess the factors that have the greatest effect on the cost-effectiveness
of screening. The most cost-effective screening strategy was Fecal Occult Blood Test
(FOBT); followed by FOBT plus aspirin, colonoscopy, and colonoscopy plus aspirin.
The ICER of FOBT was $13,014.85 compared to Natural History. The model was
sensitive to the costs of FOBT, colonoscopy, and aspirin.
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1. Introduction
Colorectal cancer (CRC) is the second leading cause of cancer-related deaths in
the United States (American Gastroenterological Association (AGA), 2006). The
American Cancer Society (ACS) estimates that in 2006, the incidence for colon and rectal
cancer cases will be 106,680 and 41,930, respectively, and estimated combined mortality
will be 55,170 deaths (ACS, 2006). Screening is used to detect CRC in healthy adults
with no signs or symptoms that suggest the presence of CRC or polyps. There are many
forms of screening used to detect CRC and recommendations for screening strategies are
abundant. The screening modalities for CRC include colonoscopy, flexible
sigmoidoscopy (FS), fecal occult blood test (FOBT), and double-contrast barium enema.
All are recommended by the ACS, the AGA, and the U.S. Preventive Services Task
Force (USPSTF). However, for the detection of CRC, no one screening test or strategy
has been recommended as the gold standard by any organization. In fact, each suggests
that any form of screening is better than none at all.

1.1 Need for Study
In 1996, the USPSTF concluded that there was sufficient evidence to recommend
screening for CRC (Bero, Grilli et al., 1998). However, for many years CRC screening
has been surrounded by controversy regarding differing guidelines.

Consequently,

utilization of screening procedures remains low. As a result, there is great concern that
the possibility of preventing and controlling this disease is being overlooked.
Recommendations for CRC screening vary among professional organizations, and patient
and physician opinions regarding the screening procedures are even more diverse. Of all
the available CRC screening procedures, no one strategy has been determined to be

optimal. Therefore, physicians are left to determine which screening procedure is best
for their patients. The various recommendations include: FOBT, FS, colonoscopy, or
barium contrast enema. While some experts believe FOBT with its annual testing is the
most cost-effective method, others believe colonoscopy should be the choice based on its
effectiveness alone. Still others recommend other screening methods.
It may be that colonoscopy would be more appealing to patients not at risk due to
its 10-year screening interval. Studies are currently being performed to identify the
barriers to CRC screening by physicians, patients, and healthcare service providers
(Klabunde, Schenck et al., 2006; Klabunde, Vernon et al., 2005; Tabbarah, Nowalk et al.,
2005). Identifying the most cost-effective screening strategy will help in optimizing
resources for screening utilization. The AGA recommends that routine screening for
CRC be widely adopted. However, according to a case-control study by Selby and
colleagues (Selby, Friedman et al., 1992), screening rates for CRC have yet to increase as
compared to screening for breast or cervical cancer in women. Despite the modest cost
of the initial screening tests, CRC is perceived as having potential costly follow-up
procedures for diagnosis and surveillance.
In the current literature, there have been no published studies utilizing a decision
analysis model comparing the screening procedures of FOBT, FS, and colonoscopy with
each other while also measuring the effectiveness of chemoprevention.

All three

screening procedures examined in this study are currently recommended by professional
organizations, such as the ACS and AGS, but there is no consensus in the literature as to
which procedure is most cost-effective. This study will evaluate the cost-effectiveness of
FOBT, FOBT plus FS, and colonoscopy, in addition to evaluating the combination of
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chemopreventive options, such as aspirin and cyclooxygenase-2 inhibitor (COX-2), with
each strategy.

1.2 Specific Aims
The purpose of this study is to conduct an economic evaluation of currently
recommended CRC screening procedures, and strategies that incorporate
chemopreventive options such as aspirin or a cycooxygenase-2 inhibitor (Cox-2). The
objectives of this study are: 1) to determine the cost-effectiveness of three of the currently
recommended CRC screening procedures alone, and also in combination with two
chemopreventive agents (nine strategies in all); 2) to determine which of the nine
strategies yields the most savings in cost, greatest increase in survival, and in qualityadjusted survival (quality adjusted life years, QALYs).

1.3 Significance
The study results will be a valuable addition to the scientific literature in the field
of CRC screening. In addition to its academic significance, the study results have
important implications for decision makers of CRC screening; physicians, administrators,
and patients. Most importantly, the results provide an economic evaluation of the nine
screening strategies modeled in this study. These nine strategies have not been modeled
together in the current literature.
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2. Background

2.1 Epidemiology of Colorectal Cancer
Colorectal cancer (CRC) is the second leading cause of cancer-related deaths in
the United States (American Gastroenterological Association (AGA), 2006). It is also the
third most common type of cancer among American men and women. In 2001, it was
estimated that 135,400 new cases of colorectal cancer developed and that 56,700
individuals with CRC died (American Cancer Society (ACS), 2001). Colorectal cancer
incidence is increasing each year while new forms of screening, prevention and treatment
are sought. The ACS estimates that in 2006, the incidence for CRC will be 148,61, and
estimated mortality will be 55,170 deaths from CRC (ACS, 2006). Ninety-three percent
of CRC cases occur in people age 50 or older and 80% of deaths occur in people over the
age of 65 (ACS, 2006). The risk of developing CRC increases with age and every person
has a one in twenty chance of developing CRC in their lifetime. Although the cause of
CRC is not known, risk factors associated with developing CRC are family history, age
(50 years and older), ethnicity, and/or lifestyle and dietary choices.
Approximately 10 percent of all colon cancers are hereditary, that is, directly
caused by specific inherited genetic abnormalities (Cancer Research and Prevention
Foundation (CRPF), 2004). While sporadic, non-hereditary cancers usually appear after
age 50, hereditary colon cancers often occur in younger people. When cancer is prevalent
in a family, but no specific genetic change has been linked to the cancers, the family is
said to have familial CRC.
With regard to race, blacks have a 40% greater chance of developing CRC than
whites (Centers for Disease Control and Prevention (CDC), 2002). The five year survival
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rate of CRC is higher for whites than blacks with localized cancer (90% versus 83%,
respectively) and regionally spreading cancer (65% versus 53%) (Surveillance,
Epidemiology, and End Results (SEER), 2003). These survival differences exist even
when other factors, such as age, gender, and geography, are considered. Over the last
decade there has been a decrease in death due to CRC (SEER, 2003). The death rate for
white males and females dropped between 1990 and 1998, 2.2% and 1.8% respectively.
Death rates have also dropped for blacks in that same time period, although
approximately 50% of that for whites (CDC, Morbidity and Mortality Weekly Report,
2002).

This drop in CRC deaths may be attributable to a shift in emphasizing cancer

prevention by many national programs. March is National CRC Awareness month, and
the symbol of a blue star was recently introduced by the National Colorectal Cancer
Roundtable (NCCRT) and will now represent the fight against colorectal cancer just as
the pink ribbon signifies breast cancer and the red ribbon depicts HIV/AIDS. Also, the
CDC’s CRC Prevention and Control screening campaign informs men and women aged
50 years or older about the importance of having regular CRC screening tests. Many
public and private insurers are beginning to cover CRC screening. In the state of West
Virginia, the Public Employees Insurance Program (PEIA) provides 100 percent
coverage for CRC screening for all employees over the age of 50.

Detection of CRC
Colorectal cancer typically grows slowly over a period of several years. The
precancerous lesions are small benign growths called polyps.

Early detection and

removal of polyps (polypectomy) is the optimal method of preventing the development of
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CRC (AGA, 2002). Although many cases are asymptomatic, the identification of
symptoms can aid in the early detection of CRC. Symptoms may include: blood in stool,
change in bowel habits, abdominal pain, continuous feeling the need for bowel
movement, and fatigue. Because of the non-specific nature of many of these symptoms,
they are often ignored, especially at the onset of the disease.
Malignancy usually starts in the innermost layer of the sigmoid colon and moves
outwardly as it progresses. As the tumor grows through the layers of tissue, the extent of
penetration determines the stage of the disease. Identifying the stage of CRC helps to
determine treatment strategies and provides an estimate of the survival rate for the
patient. Also, the stage of disease is the strongest determinant of prognosis with the fiveyear survival of patients in stage four (the most advanced stage) estimated to be less than
ten percent. Table 1 identifies and describes the various stages of colorectal cancer.

TABLE 1-1. Stages of Colorectal Cancer
Stage 0
Stage 1
Stage 2
Stage 3
Stage 4
Recurrent

The cancer is in the earliest stage and has not grown beyond the inner layer
of the colon.
The cancer has grown through the inner layer of the colon but has not spread
through the colon wall.
The cancer has grown through the wall of the colon but has not spread to
nearby lymph nodes.
The cancer has spread to nearby lymph nodes, not to other parts of the body.
The cancer has spread to distant sites, such as other organs.
The cancer has returned after treatment. It may recur in the colon or other
parts of the body.
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2.2 Colorectal Cancer Screening
Screening is used to detect CRC in healthy adults with no signs or symptoms that
suggest the presence of CRC or polyps. Individuals who present with signs or symptoms
of CRC should be offered appropriate diagnostic evaluation.

Choice of screening

strategies should be based on both patient preference and on an individual patient’s level
of risk, which takes into account their personal and family medical history.
Currently there are many forms of screening used to detect CRC and
recommendations for screening strategies are abundant.

The screening modalities for

CRC include FOBT, FS, colonoscopy, and double-contrast barium enema (DCBE). All
are recommended by the ACS, the AGA, and the U.S. Preventive Services Task Force
(USPSTF). However, for the detection of CRC, no one screening test or strategy has
been recommended as the gold standard by any organization. It is recommended that at
least one screening strategy be employed with the patient and physician determining the
most appropriate method.
In 1996, the USPSTF concluded that there was sufficient evidence to recommend
screening for CRC (Bero, Grilli et al., 1998). However, for many years CRC screening
has been surrounded by controversy regarding which of the various guidelines to utilize.
As a result of this ambiguity, and the low compliance rates of screening, many physicians
tend to give priority to other preventive services. For patients, health policy factors such
as access to care, costs, and reimbursement have been shown to influence compliance
with CRC screening (Batelle Corp., 1998). The National Colorectal Cancer Roundtable
(NCCRT) has found that the majority of adults in the U.S. are not currently being
screened for CRC (NCCRT, 2005). This limits the opportunity to reduce CRC-related
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mortality by 50% or more as envisioned by the Colorectal Cancer Review Group
(National Cancer Institute (NCI), 2000). A report by the NCCRT states that to increase
CRC screening rates, the issues of patient and physician barriers to screening, lack of
universal insurance coverage, lack of incentives to motivate adherence, and expanded
infrastructure must be addressed (Levin, Smith et al., 2002).

Efforts are already

underway to promote the importance of colorectal cancer screening and increase its use.
For example, the CDC has implemented a program called “Screening for Life” to inform
men and women aged 50 years or older about the importance of having regular CRC
screenings.

Partners in this initiative include the Center for Medicare & Medicaid

Services (CMS), the NCI, and local health departments.
Although studies have provided evidence that screening is effective in reducing
mortality from CRC as mentioned previously, utilization of screening services is low. In
a study by the CDC using 1999 Behavioral Risk Factor Surveillance System (BRFSS)
data, only 44% of respondents (male and female, >49 years of age) reported undergoing
any form of CRC screening (colonoscopy, FS, or FOBT) within the recommended period
of time (Sandler, Halabi et al., 2003). The survival rate of CRC is much higher when the
cancer is detected early. For white males, the five-year survival rate for cancer detected in
the early, localized state is 90%, as compared to detection in a regionally spreading state
which has a five-year survival rate of 65%.
Studies have been conducted to determine possible barriers to CRC screening for
both patients and physicians. Woolf and colleagues (Woolf, et al, 2000) found that the
primary barrier for patients is the negative opinion they have regarding the screening
procedures. Many patients associate pain or discomfort with CRC screening, making
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them less likely to discuss this concern with their physician. Many physicians, though
they may know the importance of CRC screening, still do not recommend screening
(USPSTF, 1996). Some physicians are aware of the most recent guidelines for CRC
screenings, but may not be able to accurately assess the risk associated with individual
patients. They may be limited by restrictions on patients’ insurance, or they may not be
impressed by the data that supports the benefit of CRC screening (USPSTF, 1996). Some
healthcare professionals report failure to recommend a FOBT due to forgetting it,
thinking that the test is ineffective, or not wanting to inconvenience patients (Vernon,
1997; Peterson and Vernon, 2000). When physicians report reasons for not offering
sigmoidoscopy, they cite discomfort for the patient, lack of time, little probability of
detecting a significant lesion, their own inconvenience, insufficient training or experience
in performing the procedure and cost (Batelle Corp., 1998; Cooper, Fortinsky et al.,
1998).

Fecal Occult Blood Test
The FOBT, also known as the stool blood test, is a non-invasive method of CRC
screening recommended to be performed yearly. This test detects traces of blood in the
stool, which can be a sign of CRC. The test consists of individuals obtaining samples of
stool using an at-home kit. The samples are then sent to a lab for testing. Sensitivity of a
single FOBT is low, around 30-50%, but repeated annual testing can detect as many as
92% of colorectal cancers (Reeves, Newcomb et al., 1996). Many trials have shown that
annual FOBT screenings can reduce the mortality of CRC in the range of 15 to 33%
(Kune, 2000; Arguedas, 2001; Ladabaum, 2001; Lieberman, 2001; Autier, 2003; Daniels,
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1995). One concern is that false positive FOBT test results can lead to unnecessary
diagnostic exams, usually colonoscopy, which increases cost and may cause discomfort
for patients.
A newer type of stool blood test is the fecal immunochemical test (FIT, or
iFOBT). This test is performed differently than the FOBT. With iFOBT, a special brush
is used to capture a water sample from within the toilet bowl – it is not necessary to
handle the stool. Unlike FOBT, iFOBT will not react with non-human hemoglobin (a
component of red blood cells), vitamins, medications, or peroxidase found in some foods
that can lead to false positive test results. This test may be more specific for detecting
loss of blood from the lower part of the intestine because this blood is less degraded
during transit. In April 2002, the ACS Colorectal Cancer Advisory Group concluded that
the iFOBT has some advantages that merit revision of their guideline statement for
FOBT, to include the iFOBT.

Based on the advisory group’s report, the ACS’s

Recommendations for Screening and Surveillance for the Early Detection of
Adenomatous Polyps and Colorectal Cancer now include the statement, "in comparison
with guaiac-based tests for the detection of occult blood, immunochemical tests are more
patient-friendly, and are likely to be equal or better in sensitivity and specificity."

Flexible Sigmoidoscopy
Flexible sigmoidoscopy (FS) is a procedure in which a thin, flexible, lighted tube
with a tiny video camera on the end is inserted into the rectum and lower third of the
colon. The scope allows inspection of the rectum and the sigmoid colon. This allows the
physician to examine the inside of the rectum and the lower colon to find and remove any
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polyps that have developed. For screening purposes, FS is recommended every five
years by the ACS and the AGA. The interval is shorter than that of colonoscopy because
FS is a less sensitive test. Screening with FS appears to detect about 70% of all advanced
neoplasia (stages three and four) in the colon, and the detection rate is upwards of 75% if
FS is combined with FOBT (Lieberman, Weiss et al., 2001).

Fecal Occult Blood Test plus Flexible Sigmoidoscopy
In addition to the ACS, the AGA and the USPSTF also recommend that FOBT
and FS be performed together for CRC screening (Winawer, Fletcher et al., 2003;
USPSTF, 2002). The USPSTF suggests that when both tests are used, FOBT should be
performed first. A positive result is an indication for colonoscopy, obviating the need for
the FS. If either FOBT or FS yields abnormal results, complete colonoscopy should be
performed.

Colonoscopy
Colonoscopy is the most specific and most sensitive of all the screening
strategies. Consequently, this screening method is able to detect more cases of CRC or
large polyps which can then be removed either by an attachment to the colonoscope or
surgically (DuBois, Giardiello et al., 1996). Colonoscopy, like FS, is a procedure in
which a thin, flexible, lighted tube with a tiny video camera on the end is inserted into the
rectum and colon. This allows the physician to examine the inside of the rectum and
entire colon to find and remove any polyps that have developed. Before a colonoscopy is
performed, a patient must take a hypersomotic laxative such as magnesium citrate or
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dibasic sodium phosphate. These solutions are used to empty and prepare the colon for
the procedure. However, colonoscopy involves greater inconvenience, risk, and cost to
patients than the other screening tests available. Risks of colonoscopy include discomfort
during the procedure and possibly after the procedure, gastrointestinal bleeding,
perforation of the colon, and death, although the risk of death is quite low. It is estimated
that the risk of death from perforation-related complications from colonoscopy is about
0.11% with older persons and those exhibiting symptoms are also at greater risk
(Ransohoff, Land et al., 1991).
Colonoscopy is the most expensive procedure and can cost between $975 and
$1500 (Wagner, et al., 1996; Frazier, et al., 2000; Khandker, et al., 2000). This is
significant when compared with FOBT ($35-$55), FS ($250-$400), and Double Contrast
Barium Enema (DCBE) ($250-$500) (Pignone, Saha et al., 2002). The recommendation
by the ACS and AGA is for colonoscopy to be performed on an average-risk patient
every ten years beginning at the age of 50, otherwise every 1-2 years for an individual at
high-risk. High risk individuals are those who have previously had CRC, or have had a
close blood relative, such as a parent or sibling, who has had CRC. According to
Lieberman (Lieberman, Holub et al., 2005), asymptomatic screening accounts for almost
a third of colonoscopies performed in persons age 50 year and older. As of July 1, 2001,
United States Federal law entitled Medicare beneficiaries to a colonoscopy every ten
years, however the proportion of physicians recommending this screening to these
individuals remains low (CMS, 2001; Peleg, Maibach et al., 1996).

Additionally,

Lieberman (Lieberman, Holub et al., 2005) found that colonoscopy utilization varies
based on age, gender, and race.
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Colonoscopic screening, although effective, may not be the most desirable
screening method for everyone. Data from a number of recent polyp prevention trials
suggests that colonoscopy with polypectomy may not lead to a large reduction in CRC
cases or mortality (Pabby, 2005; Robertson, Greenbert et al., 2005). Also, screening
colonoscopy has a rate of serious complications that may be as much as ten times the rate
for FS screening (Nelson, McQuaid et al., 2002). Thus, screening colonoscopy must be
weighed against the less invasive screening tests to determine the incremental benefits.

Double-Contrast Barium Enema
Double-contrast barium enema (DCBE) is another form of screening, which is
also recommended by the ACS. It is suggests that DCBE be performed once every 5-10
years. This procedure involves an X-ray examination of the colon and rectum. The
colon is filled with a liquid contrast material containing barium. The barium is not
excreted, which allows the outline of the colon to appear on the X-ray film. In a casecontrol study by Mandel and colleagues (Mandel, Bond et al., 1993), screening with
DCBE was associated with a 33% reduction in CRC deaths. The cost of the DCBE is
lower than that of the colonoscopy, but higher than FOBT and FS. Patient concerns
associated with DCBE include the feeling of discomfort during the procedure. Also,
there is a very small risk of perforation (1/25,000) which may occur due to the pressure
exerted on the colon wall during the procedure (Glick, Ralls et al., 2000). However, the
effectiveness of barium enema is unclear since documentation is minimal and usage has
declined.

The current study did not include DCBE as a screening strategy due to

uncertainty regarding its effectiveness.
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The Future of CRC Screening
There are emerging technologies which hold substantial promise in CRC
screening. These include virtual colonoscopy (Mulhall,Veerappan et al., 2005), magnetic
resonance (MR) colonography and fecal DNA tests (Osborn and Ahlquist, 2005). Virtual
colonoscopy (or CT colonography) is non-invasive and does not cause major
complications. It is an x-ray technique using high-speed CT scanning and complex
software to obtain a two dimensional image of the colon. It differs from colonoscopy in
that it does not involve the direct visualization of the surface of the colon using highresolution video equipment. As with colonoscopy, this procedure requires the same type
of bowel preparation and may still be uncomfortable for the patient. With colonoscopy,
the discomfort arises from the insertion of the colonoscope and air insufflation.
However, the discomfort of virtual colonoscopy is from air insufflation only, making the
procedure somewhat less uncomfortable.
A study by Pineau and colleagues (Pineau, Paskett et al., 2003) determined that
virtual colonoscopy has a high sensitivity and specificity of detecting significant
colorectal lesions.

The sensitivity and specificity for an precancerous polyp was

determined to be 93.8% and 96.0%, respectively in a study by Prickhardt and colleagues
(Prickhardt, Choi et al., 2003). In a 1999 cost-effectiveness study, it was found that
screening with virtual colonoscopy costs $24,586 per life-year saved, compared with
$20,930 per life-year saved by colonoscopy screening (Sonnenberg, Delco et al., 1999).
Furthermore, the authors concluded that screening by colonoscopy remained more cost-

14

effective even if the sensitivity and specificity of virtual colonoscopy both rise to 100%.
For this reason, virtual colonoscopy was not used as a comparator in this study.
However, patients who choose not to have a standard colonoscopy, whether due
to the invasiveness of the procedure, or the slightly increased risk of bowel perforation,
may then choose to have a virtual colonoscopy. However, a significant disadvantage of
virtual colonoscopy is that a subsequent colonoscopy must be performed if polyps are
discovered during the procedure and are to be removed.

Although technology is

continually improving, some of the new screening procedures, such as genetic (DNA)
testing of stool samples, are not ready for widespread use.

2.3 Treatment of Colorectal Cancer
There are three main approaches to the treatment of colorectal cancer; surgery,
radiation therapy, and chemotherapy. In addition, targeted therapies called monoclonal
antibodies are now being administered as well. Two or more types of treatment may be
used at the same time or one treatment may follow the other treatment, depending on the
stage of the diagnosed cancer.
2.3.1 Surgery
Colorectal cancer treatment is based mainly on the size, location, and extent of the
lesion. The primary treatment for CRC is surgery, which almost always involves the
removal of part of the rectum or colon where the cancerous lesion is found. This
procedure is called a partial colectomy. The degree to which the cancer has spread
determines the amount of colon removed. The healthy parts of the colon or rectum are
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then reattached. Also, a colostomy may be performed if, after the diseased portions of
the colon, rectum and tissue are removed, the healthy tissues cannot be sewn back
together. In this procedure, part of the colon is brought through an incision in the
abdominal wall and formed into an artificial opening (stoma) to allow the discharge of
feces into a lightweight bag attached to the skin. A colostomy may be temporary or
permanent. A temporary colostomy is sometimes needed to allow the lower colon or the
rectum to heal after surgery. Later, in a second procedure, the surgeon will reconnect the
healthy sections of the colon or rectum.

2.3.2 Radiation
Radiation, used to destroy cancer cells and/or shrink tumors, can be used alone or
in addition to surgery. Typically, radiation is used in stages two, three and four of CRC.
This is to ensure all cancer cells are suppressed or destroyed. Unfortunately, this is not
always successful in later stages of disease (stages three and four). Radiation therapy
may be used before surgery to shrink a tumor so that it is easier to remove, or may be
utilized following surgery to decrease the chances of cancer occurrence. There are two
methods used to expose the colon/rectum to radiation: 1) using a machine outside the
body, referred to as external radiation therapy; or 2) administering radioactive materials
through thin plastic tubes into the intestinal area, called internal radiation therapy.
Radiation therapy is usually given on an outpatient basis for approximately five to six
weeks (five days a week). Generally, radiation has fewer side effects for the patient than
the alternative, chemotherapy.
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2.3.3 Chemotherapy
Chemotherapy is used to destroy cancer cells. Given orally or via the
bloodstream these drugs enter the bloodstream and travel through the body to kill cancer
cells outside of the colon. Chemotherapy may be given after surgery to kill any cancer
cells that remain or as a preventive measure after surgery to assure the cancer does not
spread. This preventive measure is called adjuvant therapy. Like radiation therapy,
chemotherapy is usually utilized in the second, third and fourth stages of CRC, but is not
always successful during the latter two stages of CRC. Chemotherapy is most often
given in cycles – a treatment period followed by a rest period to allow the bone marrow
to recover, then another treatment, and so on. There is some debate about how many
cycles of chemotherapy should be used in the treatment of colon and rectal cancer.
Generally, after surgery, when patients receive chemotherapy alone for CRC, they are
given between six to 12 cycles. When chemotherapy is administered along with radiation
therapy, the patient may get two cycles before radiation therapy, two more cycles with
the radiation therapy, and two to eight cycles after the radiation therapy. The exact
schedule for chemotherapy depends on the specific drugs used. Some drugs may be
given for a period of one week to two weeks, followed by a period of about 2 weeks to
recover from the bone marrow suppressive effects.
Efficacy of 5-fluorouracil (5-FU) plus leucovorin (LV) as adjuvant chemotherapy
for CRC has been established. Recently, large multicenter randomized controlled trials
evaluating value of new regimens such as oxaliplatin+5-FU plus LV, capecitabine, and
uracil-tegafur (UFT) plus LV, as compared with 5- FU plus LV, have been conducted.
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Although further integration of targeted compounds including cetuximab and
bevacizumab into adjuvant therapy may be promising, cost issues have begun to emerge.

2.4 Chemoprevention and Colorectal Cancer
Chemoprevention is the use of drugs prophylactically to decrease the risk of
developing cancer, reverse the pre-malignant process and re-regulate cellular growth and
differentiation (Daniels and McKee, 1995). Currently, several drugs are thought to be
effective chemopreventive agents in the fight against CRC. These medications include
non-steroidal anti-inflammatory drugs (NSAIDs), such as aspirin, and COX-2 inhibitors.
Epidemiological evidence establishes an association between NSAID use and the
reduction in incidence of CRC (Suh, 1993; Muscat, 1994; Logan, 1993; Greenberg,
1993).

For the most part, this association is based on observational studies.

Unfortunately, interpretation of such studies may be misleading. Still, many experts will
not rule out the possibility that aspirin has a positive impact on CRC prevention. Studies
have also been conducted to assess the possibility of combination therapy. However,
chemoprevention should not replace periodic screenings with methods such as FOBT,
FS, and colonoscopy (Ladabaum, Chopra et al., 2001).

2.4.1 Aspirin
Aspirin and other similar NSAIDs are the most widely studied agents in the
chemoprevention of CRC (Ladabaum, Chopra et al., 2001). This class of drugs has
proven effective as modest chemopreventive agents. Investigators at Dartmouth Medical
Center conducted a randomized, double-blinded study including 1,000 participants in
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three randomized groups.

The three groups received either 81 milligrams or 325

milligrams of aspirin, or a placebo. It was found that there was about a 19% reduction in
polyp (precursor for CRC) recurrence in the low (81mg) aspirin dose group (Baron, Cole
et al., 2003).

Recent observations suggest that aspirin and other NSAIDs have a

chemopreventive benefit. A case-control study demonstrated a 40-50% reduction in the
risk of adenomas and CRC among patients who took aspirin (Baron and Sandler, 2000).
Two smaller case-control studies also demonstrated similar benefits with aspirin; but both
lacked significant statistical power (Thun et al., 1991 and Thun et al., 1993).
Although aspirin has been found to provide a degree of protection against CRC,
there is a risk of adverse side effects such as gastrointestinal ulceration. Aspirin is
contraindicated in patients who have a history of gastrointestinal bleeds, and in those who
have a triad of symptoms including asthma.

In a

2001 study by Ladabaum and

colleagues (Ladabaum et al., 2001), the authors reported that aspirin chemoprophylaxis
alone remained generally non-cost-effective for those adhering to screening.

They

concluded that aspirin therapy should not substitute for screening; however aspirin may
be used to supplement screening.

When used as an adjunct to FOBT/FS, aspirin

increased costs but decreased life-years due to related complications.

Aspirin also

yielded a small benefit in life-years as an adjunct to colonoscopy, but with a high
incremental cost.
Chan and colleagues (Chan et al., 2005) suggest that optimal chemoprevention for
CRC requires long-term use of aspirin at doses substantially higher than those
recommended for prevention of cardiovascular disease. Nonaspirin NSAIDs appear to
have a similar effect. However, the significant benefit of aspirin is not apparent until
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after a decade of use, with maximal risk reduction at doses greater than 14 tablets (325
milligrams) per week. However, the dose-related risk of gastrointestinal bleeding must
also be considered.

2.4.2 Cox-2 Inhibitors
Enzymes known as cyclooxygenase 1 and 2 (COX-1 and COX-2) are
important to the function of the human body. They both convert arachidonic acid to
prostaglandins, which are then implicated in the mediation of pain, inflammation, cell
proliferation and other key biologic responses. It has long been thought that COX-1 and
COX-2 carry out the same biochemical reactions but that they are regulated differently —
that is, the switches for activating them are different. COX-1 inhibitors are simple,
competitive, reversible inhibitors that compete with arachidonic acid for binding to the
COX active site. The most commonly prescribed drugs in this class are ibuprofen,
piroxicam, sulindac, and naproxen.
COX-2 is induced during inflammation and tissue repair. The primary benefit of
COX-2 inhibitors is their ability to spare COX-1 and preserve gastrointestinal health.
Also, COX-2 appears to be associated with colorectal adenocarcinomas, in that more than
80% of colon cancers express COX-2, compared with normal tissue. COX-2 inhibitors
have been shown to significantly inhibit both early and late stages of chemically induced
CRC in rats (Reedy et al., 2000). However, human data is not yet available to support
these findings. Additionally, a 2003 study by Tuynman and colleagues (Tuynman et al.,
2003) determined that an anti-carcinogenic effect had been shown specifically in
selective COX-2 inhibitors in animal models. It has also been found that selective COX-
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2 inhibitors have fewer adverse effects than the non-selective NSAIDs and are seen as
promising chemopreventive agents.
A study in 2001 by Arguedas and colleagues (Arguedas et al., 2001) compared
the therapy of COX-2 inhibitors with CRC surveillance using colonoscopy. The study
employed a Markov model with states representing the natural history of adenomas after
endoscopic polypectomy (O’Leary et al., 2004). The results suggest that long-term COX2 inhibition is a more expensive, yet more effective, therapy when compared with
colonoscopic surveillance for prevention. Arguedas and colleagues (Arguedas,
Heudebert et al., 2001) also reported that COX-2 chemoprevention for surveillance in
average-risk post-polypectomy patients is a more expensive strategy compared to
colonoscopic surveillance. Another study by Ladabaum and colleagues (Ladabaum,
Scheiman et al., 2003) concluded that although COX-2 inhibitors used as an adjunct to
screening may increase life expectancy, it does so at prohibitive costs ($233,300 per life
year saved).
At the end of September 2004, Merck &. Co., Inc. announced a voluntary
withdrawal of VIOXX (rofecoxib), its COX-2 inhibitor. The decision to immediately
withdraw the product was based on new, three year data from a prospective, randomized,
placebo-controlled clinical trial, the APPROVe (Adenomatous Polyp Prevention on
VIOXX) trial. The trial, before being halted, was designed to evaluate the efficacy of
VIOXX 25mg in preventing recurrence of colorectal polyps in patients with a history of
colorectal adenomas. In this study, there was an increased relative risk for confirmed
cardiovascular (CV) events, such as heart attack and stroke, beginning after 18 months of
treatment in the patients taking VIOXX compared to those taking placebo. It may cause
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heart attack and stroke due to its effect on platelets. The results for the first 18 months of
the APPROVe study did not show any increased risk of confirmed CV events on
VIOXX, and in this respect are similar to the results of two placebo-controlled studies
described in the current U.S. labeling for VIOXX.
The National Cancer Institute’s (NCI) Adenoma Prevention with Celecoxib
(APC) Trial is a clinical trial to determine if celecoxib, which inhibits the enzyme COX2, reduces the occurrence of new adenomas (precancerous polyps) in the colon and
rectum of people who have already had such a polyp removed. The trial enrolled
participants from late 1999 through February 2002 and was scheduled to be completed by
Spring 2005. The use of celecoxib in the APC Trial was suspended on December 17,
2004 because analysis by an independent Data Safety and Monitoring Board (DSMB)
showed that the risk of major fatal and non-fatal cardiovascular events (cardiovascular
death, heart attack, stroke, or heart failure) was 2.5 times higher for participants taking
the drug compared to those on a placebo. Investigators in the APC trial immediately
suspended study drug use, although the participants are under observation for the planned
remainder of the trial. A December 2004 analysis of a similar study sponsored by Pfizer,
called the PreSAP cancer trial, did not show an increased risk of cardiovascular events.
APC investigators recently published a full report of the analysis of cardiovascular events
on the trial (Solomon, McMurray et al., 2005). In this analysis, celecoxib use for an
average of almost 3 years was associated with a dose-related increased risk of serious
cardiovascular events (cardiovascular death, heart attack, stroke, or heart failure).
The NCI, despite the revelations about rofecoxib and celecoxib, has not
abandoned the idea of using COX-2 inhibitors to reduce patients' risk of CRC. The web
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site ClinicalTrials.gov showed in March 2005 that recruitment continued for an NCIsponsored study of celecoxib in the prevention of CRC in patients with familial
adenomatous polyposis. The NCI is attempting to continue on with the celecoxib trials in
high-risk cohorts because the potential benefits may outweigh potential risks. As for the
NCI-sponsored studies of COX-2 inhibitors in patients at lower risk of colorectal
adenoma, that line of research is not currently being evaluated. The NCI now focuses its
chemoprevention efforts with COX-2 inhibitors on high-risk patients—those with a 40–
100% lifetime risk of developing a specific cancer.

One goal of NCI's continuing

research is to identify patients with relatively low safety concerns from long-term
exposure to COX-2 inhibitors who would benefit greatly from the reduction in cancer
risk.
Recent studies conducted by New Zealand and American revealed that Celebrex
(Pfizer’s brand of celecoxib), increases the risk of heart attacks in patients and is not any
safer than similar medications that have been withdrawn from the market (Caldwell et al.,
2006). However, in 2005, the Food and Drug Administration (FDA) concluded that the
benefits of Celebrex outweighed the risks, thus making it the only remaining Cox-2
inhibitor available on the market. The FDA did require Celebrex to carry a "black box"
warning alerting consumers of the heightened risk of heart attacks.
A new study, which used data from six previous clinical trials of Celebrex
involving more than 12,000 patients, employed a meta-analyses to provide an overall
answer to the ongoing Celebrex controversy. Researchers compared Celebrex's
cardiovascular risks with those of a placebo drug and with a class of common analgesics,
which have also been associated with heart attacks and strokes. The study reported that
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the use of Celebrex more than doubled the risk of heart attacks compared to a placebo
and had a 1.88-fold increase in comparison with other painkillers (Caldwell, Aldington et
al., 2006).
Researchers may be able to develop new drugs with fewer side effects once they
better understand how COX-2 inhibitors fight cancer and why the drugs carry a
cardiovascular risk. The drugs may work by other means in addition to inhibiting the
COX-2 enzyme.

2.5 Cost of Colorectal Cancer
The estimated direct cost for the treatment of CRC in the United States is over
$6.5 billion annually (Schrag and Weeks, 1999). Among malignancies, this is second
only to breast cancer at $6.6 billion per year. In a study sponsored by the NCI, the U.S.
Office of Technology Assessment (OTA) estimates that treating a case of early stage
cancer (stages one and two) costs approximately $35,000; while treating late stage cancer
(stages three and four) adds an additional $10,000 to the cost. According to the ACS,
only 37% of colorectal cancers are currently detected at a localized stage (ACS, 2006).
Thus, the overall cost of treating CRC is much higher than it would be if a greater
percentage of cases were detected early. Proponents of CRC screening hope that if
utilization of screening tests increases, the percentage of cancers detected at an earlier
stage will also increase. This may then lead to a reduction in treatment costs. Compared
with screening for other types of cancer, colonoscopy for CRC screening has been shown
to be more cost-effective. Colonoscopy (every ten years) has an average estimated cost
of approximately $12,000 per life year saved as compared with breast cancer screening
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($22,000) and cervical cancer screening ($250,000) (Pignone, 2002; Wagner, 1996;
Frazier, 2000; Khandker, 2000; Sonnenberg, 2000; Vijan, 2001).
According to the NCI and the CDC, the direct costs associated with the treatment
of CRC in 1999 dollars were $4.8 billion (Colon Cancer Alliance, 2001). Emergency
room visits and visits to hospital outpatient departments, about 50,000 and 350,000
respectively accounted for $309.9 million of this figure. Approximately $19.5 million
was spent on the cost of drugs to treat CRC, excluding chemotherapeutic agents
administered in the physician office setting. In addition, hospitalizations accounted for
$3.1 billion, physician fees for $1.1 billion, and home health care, hospice care and
skilled nursing cost $341 million. Adjusting this total for inflation, the total direct costs
were nearly $6.4 billion in 2003.
The adjusted amount for indirect costs for 2003 was approximately $130.1 million
(Colon Cancer Alliance, 2001). There were approximately 2.3 million days of work lost
in 1998, for a work loss equivalent of $70.9 million in lost wages among the working-age
population. In addition to lost wages, indirect costs may be higher when lost productivity
due to morbidity is accounted for.

2.6 Quality of Life
Quality of life (QOL) has been defined by the World Health Organization (WHO)
as an individual's perception of their position in life in the context of the culture and
value systems in which they live and in relation to their goals, expectations, standards and
concerns (WHO, 1998). From the time of diagnosis, the QOL of every cancer patient and
survivor is affected in some way, whether it be physical or emotional well-being, social
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and personal relationships, spirituality, personal fulfillment, or leisure planning. These
effects can disrupt patient relations with family and friends, and effect socialization,
career, and financial stability. Screening, diagnosis, and treatment of CRC all have
significant short and long-term effects on patients’ QOL. These effects may include pain
and discomfort from screening procedures or from having part of the colon resected
during surgery. Also, patients may suffer from emotional stress from being diagnosed
with CRC, or throughout treatment, including adverse effects from chemotherapy.
Physical QOL effects, such as the pain or discomfort from screening, and/or follow-up
procedures, may also help explain why colorectal screening rates are low.
Trentham-Dietz and colleagues (Trentham-Dietz et al., 2003) conducted a study
of 726 Wisconsin women diagnosed with colorectal cancer during the period 1990–1991.
A follow-up survey was given eight years later to the 443 surviving participants. The
study concluded that over the long term, factors attributable to aging, body weight, and
chronic medical conditions play more dominant roles in determining physical and mental
health than factors related to the initial CRC diagnosis.
In decision analysis, strategies are evaluated by comparing the overall benefits
expected from pursuing each strategy. This is known as the expected value. The
expected value of each strategy is calculated by multiplying the value of outcomes
(utilities) by their probability of occurrence. In this way, investigators can differentiate
between various strategies and choose the optimal strategy or path of events. Utilities are
values that represent an individual’s preferences for specific outcomes or health states
under uncertainty and provide an approach to incorporate health-related QOL in a
decision model. Utilities are measured on a scale of 0 to 1, with 0 representing death and
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1 representing a state of full or perfect health.

In the model, utilities are used to place

value on outcomes and can be derived from published literature, direct elicitation, or
from expert opinion.

Utility Scales
Direct utility elicitation involves using scaling methods to collect data on utilities.
Examples are standard gamble, time trade-off, rating scales, and the Health Utilities
Index (HUI). Standard gamble involves measuring an individual’s preferences between a
certainty of one outcome and a gamble of two possible outcomes. Time trade-off
involves asking subjects to consider the amount of time or life expectancy they would be
willing to trade in order to survive in various health states. The HUI is used to describe
health status and produce utility scores. The HUI assigns utilities by using the
mutiattribute framework. This method breaks health states into domains (attributes),
assigns a value for each domain, and calculates overall utility by multiplying together the
utilities for each attribute.

Measure of Outcome
The quality adjusted life year (QALY) is the most commonly used measure of
outcome for decision analysis. QALYs can be expressed as life expectancy in a
particular health state, multiplied by the utility in that health state, combining both
quantity and quality into a single measure. This makes it possible to compare
interventions that extend life expectancy but may result in some decrease in QOL, against
other interventions that improve the QOL without extending life expectancy. The value
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of QALYs is that they can provide a common unit that can be compared across different
disease areas or treatment groups. In this study, comparison is made across different
screening strategies for CRC.
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2.7 Cost-Effectiveness

Cost-effectiveness analysis (CEA) is a technique for comparing the value of
various clinical strategies where both the costs and effects of strategies are examined.
Generally, the effects are the outcomes of the proposed program or treatment which is
being evaluated. When a new strategy is compared with current practice one may
calculate the cost-effectiveness ratio:

Cost-Effectiveness ratio =

(cost of new strategy) – (cost of current practice)
_______________________________________
(effect of new strategy) – (effect of current practice)

This ratio measures the difference of costs and effects between current practice and a new
strategy.

2.7.1 Cost-Effectiveness Studies in CRC Screening

A meta-analysis by Pignone and colleagues (Pignone et al., 2002) compiled
results from five cost-effectiveness studies of CRC screening. Within the studies, various
strategies had incremental cost-effectiveness ratios between $5,000 and $40,000 per life
year saved (see Table 2-1).
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Table 2-1 Cost-effectiveness Ratios of Colorectal Cancer Screening Strategies in
Dollars per Life-year Saved
Study
FOBT* (annually)
FS** (every 5 years)

Wagner Frazier Khandker
Sonnenberg
Vijan
(1996)
(2000)
(2000)
(2000)
(2001)
11,725
17,805
13,656
10,463
5,691
12,477
15,630
12,804
39,359
19,068

Combination FOBT* & FS** 13,792

22,518

18,693

-

17,942

DCBE+ (every 5 years)
11,168
21,712
Colonoscopy (every 10 years) 10,933
21,889
All costs are adjusted to year 2000 U.S. dollars.

25,624
22,012

-

9,038

*

Fecal Occult Blood Test

** Flexible Sigmoidoscopy
+

Double Contrast Barrium Enema
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11,840

Pignone and colleagues (Pignone et al., 2002) also conducted a systematic review
of the cost-effectiveness of CRC screening for the USPSTF. The review concluded that
screening for CRC using FOBT, FS, combination FOBT/FS, DCBE, or colonoscopy is
cost-effective when compared to no screening, but no one screening strategy can
considered to be the “gold standard. One limitation to this review was that there was not
sufficient eveidence to determine the cause of the differences among the results of the
examined studies. The authors were not able to determine if these inconsistent results
arose from either differences of the values used in the models, or from the differing
model structures.
In a study by Vijan and colleagues (Vijan et al., 2001) , the cost-effectiveness
ratio of each screening strategy included is less than $20,000 per life-year gained across
all levels of compliance that were evaluated. The study also suggests that the cost of
colonoscopy and the proportion of cancers that arise from polyps are key factors in
determining the cost-effectiveness of screening for CRC. It was found that for the
strategy of FOBT/FS to be the optimal choice in screening, one of the following must
occur: a) 50% of CRC must arise from polyps, the compliance rate of screening must be
very high (75% or greater), and costs for colonoscopy must be moderate; or b) 50% of
CRC arises from polyps, the compliance rate is 50%, and the cost of colonoscopy is
$1,000 or more. Vijan and colleagues (2001) believe that under normal circumstances,
meeting all of these conditions is unlikely. In addition, the study notes that the benefits
of endoscopic screening by colonoscopy has not been demonstrated in randomized
controlled trials, and that the screening combination of FS and FOBT has not yet been
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evaluated in clinical studies. Thus, effectiveness estimates are soley based on CRC
natural history, particulary evolution of a precancerous polyp to a carcinoma.
Sonnenberg and colleagues (Sonnenberg et al., 2000) found that FOBT is a costeffective option compared with no screening and that FS is an expensive alternative to
FOBT. Also, colonoscopy was found to have a relatively modest incremental costeffectiveness when compared with both FOBT and no screening. Given low compliance
rates, colonoscopy every ten years is the most cost-effective means of CRC screening due
to the reduction of mortality at relatively low incremental costs. This study did not
evaluate the strategies of DCBE or the combination of FOBT/FS. The design of this
study’s model reduced the complex natural history of CRC to a few essential states and
avoided making assumptions regarding transitions. In addition, this study included a
compliance component and patients who became noncompliant with screening were
assumed to remain in that state for the remainder of their life.
The study by Frazier and colleagues (Frazier, Colditz et al., 2000) varied
compliance rates of screening from 60% to 100%. The authors concluded that CRC
screening is as cost-effective as other forms of cancer screenings. FOBT/FS (1yr/5yr)
was the most cost-effective strategy with an 80% reduction in mortality. In addition, a
single screening at age 55 using colonoscopy was found to achieve a 30%-50% reduction
in mortality. One limitation of this study is that sensitivity of FOBT initial and repeat
tests were assumed to be alike. However, polyps as well as cancers may bleed
intermittently, and other conditions may cause rectal bleeding. Therefore, an initial FOBT
may be falsely negative or positive. The sensitivity of FOBT increases with the number
of samples per stool and the number of stools sampled (USPSTF, 2002).
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In a study by Khandker and colleagues (Khandker, Dulski et al., 2000), FS every
five years and annual FOBT were the two most cost-effective strategies . However, with
low screening compliance, FOBT was less cost-effective. Also, colonoscopy every ten
years was more cost-effective when the cost of colonoscopy was reduced. Due to the
lack of definitive clinical studies on the kinetics of adenomatous polyps and growth and
spread of CRC published in the literature, assumptions in this study represent a best
guess. The study also cited the lack of definitive clinical studies on the effectiveness of
the various screening tests.
A study by Wagner and colleagues (Wagner, Tunis et al., 1996) concluded that FS
and DCBE were comparable and were more cost-effective than the other stategies
evaluated. Additionally, another report concluded that FOBT, though similar in costeffectiveness, does not deliver sensitivity equal to that seen in the Minnesota FOBT
clinical trials (Mandel, Bond et al., 1993). In that study, the sensitivity of FOBT was
found to be 80.8% and 92.2, no rehydration and rehydration of slides, respectively. As
with many studies, probabilities and utilities in this study were based on available
literature, expert opinion, or best guess assumptions. Additionally, the study recognizes
that all CRC screening tests are, in some way, uncomfortable or unpleasant to patients
and that patients’ acceptability of screening tests should be incorporated in the model.
In another study, O’Leary and colleagues (O’Leary, Olynyk et al., 2004)
concluded that FS was the most efficient strategy in terms of cost per life-year saved,
followed by colonoscopy and FOBT (approximately $11,832, $29,005 and $33,031,
respectively, in then current U.S. dollars). Colorectal cancer screening studies reviewed
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by the USPSTF (2002) indicate that CRC screening is likely to be cost-effective (less
than $30,000 per additional life year gained) regardless of the strategy chosen.
A study by Ness and colleagues (Ness, Holmes et al., 2000) found that one-time
colonoscopic screening in adults between ages 50 and 54 had a cost-effectiveness ratio of
less than $10,000. Although screening for CRC appears to be cost-effective when
compared with no screening, the study concluded that no one strategy was the most
effective or had the most desirable cost-effectiveness ratio. The lack of generalizability
of the base model assumptions in this study was a limitation. All of the assumptions in
the models were based on prevailing literature opinion, each of which was controversial.
Cost-effectiveness studies have also been performed to assess cost issues with
chemopreventive drugs. A study by Ladabaum and colleagues (2003) concluded that
COX-2 inhibitors incur substantially higher costs per life-year saved than any of the
currently recommended screening strategies alone. Although COX-2 inhibitors have
been shown to possibly increase life expectancy when used as an adjunct to colonoscopy
(every 5 or 10 years), costs are shown to be higher due to the expense of the drug.
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3. Methods
3.1 Model Structure
A Markov model was constructed to simulate the natural history of colorectal
cancer (CRC).

Figure 3-1 shows the Markov model and the allowable transitions

between health states. The Markov model was then employed in a decision analytical
model using Data TreeAge® software to compare alternative CRC screening strategies.
The following nine screening strategies are included in the model:
1) annual Fecal Occult Blood Test (FOBT)
2) annual FOBT plus aspirin
3) annual FOBT plus COX-2 inhibitor
4) annual FOBT plus Flexible Sigmoidoscopy (FS) plus 5 years
5) annual FOBT plus FS every five years plus aspirin
6) annual FOBT plus FS every five years plus COX-2 inhibitor
7) colonoscopy every 10 years
8) colonoscopy every 10 years plus aspirin
9) colonoscopy every 10 years plus COX-2 inhibitor
The first branch point on the decision tree (Figure 3-2) is a decision node
indicating a choice for CRC screening strategy. Figure 3-3, Figure 3-4, and Figure 3-5
display the structure of the arms of the decision model. Many of the arms/strategies are
similar; however, the probabilities of events employed in each arm/strategy are different.
Figure 3-3 shows the FOBT arm of the decision tree. This arm is identical for strategies
one, two, and three (FOBT, FOBT plus aspirin, FOBT plus Cox-2). The arms in the
model for strategies four, five, and six (all FOBT plus FlexSig strategies) are identical
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(Figure 3-4), and the arms with colonoscopy as a strategy (either alone or with
chemoprevention) are also very similar (arms seven, eight, and nine) (Figure 3-5).
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Figure 3-1 Allowable Transitions between Health States in Colorectal Cancer Screening
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CRCDistant

Figure 3-2 Collapsed Decision Tree of Colorectal Cancer Screening
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Figure 3-3 Structure of FOBT, FOBT plus Aspirin, and FOBT plus COX-2
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Figure 3-4 Structure of FOBT/FS, FOBT/FS plus Aspirin, and FOBT/FS plus COX-2
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Figure 3-5 Structure of Colonoscopy, Colonoscopy plus Aspirin, and Colonoscopy plus COX-2
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3.2 Allowable Transitions
A hypothetical cohort of 100,000 average-risk males 50 years of age was
evaluated in the model. The model moved the cohort through different health states
(Figure 3-1) for 35 cycle years or until death. A time horizon of 35 years was chosen
since screening for CRC has been shown not to be cost-effective once an individual is 85
years of age. A Markov cycle is a period during which individuals can transition from
one health state to another. The Markov cycle length was one year. That is, each
individual remains in a health state for a full one-year cycle before transitioning into
another state, or remaining in the same state. Transitions between health states are
governed by probability values, known as transition probabilities. For example, if a
patient is in the WELL state, after one year they may stay in the WELL state or move to
the WELL WITH POLYP HISTORY, CRC-LOCAL, CRC-REGIONAL, CRCDISTANT or DEAD state. The DEAD state is an absorbing state, once an individual
enters this state they cannot transition to another state. In reality, transitions occur at any
time. However, in the model, they occur at discrete times. To best approximate the
continuous reality, the assumption is made that transitions occur, on average, halfway
through each cycle. Thus, we use half-cycle corrections to approximate the number in
the middle of a cycle that begins halfway through the previous cycle and ends halfway
through the subsequent cycle. This balances the over- and under-estimation.

Screening Arm Structure
In the FOBT arm, the entire cohort begins in the “Well” state.

Then, an

individual either survives or dies. Those individuals who die within a cycle year have
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died of causes other than CRC.

If they survive, they would either have a normal

(negative) or abnormal (positive) screening result. If the screening is normal, they
remain in the “Well” state for the next cycle. If the screening is abnormal, a diagnostic
colonoscopy is performed. During the diagnostic colonoscopy, if a polyp is found, a
polypectomy is performed and the individual moves to the “Well with Polyp History”
state for the next cycle. If no polyp is found, there is a possibility that cancer may be
found. If cancer is not found, the abnormal (positive) test may have been a false positive
and the individual would remain in the “Well” state for the next cycle. If it is cancer, it is
either “Metastatic” or “Non-metastatic” and the individual will move to the
corresponding state (CRC-D for metastatic; CRC-L or CRC-R for local or regional,
respectively).
Upon entering the “Well with Polyp History” state, an individual will either
survive or die.

A surveillance colonoscopy is performed every 3 years after a

polypectomy. If no polyp is found after the first surveillance colonoscopy, the individual
will return to the “Well” state. If the colonoscopy returns an abnormal result (positive),
either a polyp or cancer will be found and the individual will move to the corresponding
state.
In the Local (CRC-L) and Regional (CRC-R) cancer states, an individual will
either survive or die. After surviving, assuming 100% treatment rate, either the patient
will be “cured” or “not cured”. If “cured”, the individual will move to the “Well with
CRC_L (or CRC_R) History” state. If the individual is not cured, they will remain in the
current state or progress to the next cancer state. In the “CRC_D” state, an individual
either survives or dies.
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After being cured of cancer, individuals enter either the “Well with CRC_L
History” state or the “Well with CRC_R History” state. In these states, the individual
either survives or dies. Upon surviving, a surveillance colonoscopy is performed every
five years to check for recurrent cancer. If the colonoscopy is “normal” the individual
stays in the current state. Otherwise, either a polyp or cancer will be found and the
individual will move to the corresponding state.
All nine of the strategy arms move the cohort through the model in a similar way
as that described above for the FOBT arm. However, the length of time an individual is
in a state varies due to the different screening intervals for different screening strategies.
In the FOBT/FS arm individuals have an annual FOBT then a follow-up FS every five
years if the FOBT is “normal”. If an FOBT is “abnormal” at any time, a diagnostic
colonoscopy would be performed. A colonoscopy is performed every ten years for those
strategies employing it as the screening procedure.

3.3 Baseline Probabilities and Utilities
The probabilities of various events and associated costs were the two types of data
required to populate the decision analysis model. Probabilities of various events in the
model were obtained through a review of the published literature, such as Ness and
colleagues (Ness at al., 1998), Wagner and colleagues (Wagner et al., 1996), and
Khandker and colleagues (Khandker at al., 2000). Both Khandker and colleagues and
Wagner and colleagues conducted cost-effectiveness evaluations of three of the screening
strategies used in this study (FOBT, FOBT plus FS, and colonoscopy). Previous studies
have been performed to assess the effectiveness of aspirin (Ladabaum, Chopra et al.,
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2001; Sandler et al., 2003) and COX-2 inhibitors (Steinbach, 2000, Arguedas 2001,
Rahme 2003) as chemopreventive agents for CRC. Estimate values for each variable
used in the decision tree were selected from such studies (see Table 3-1).
Incidence and mortality rates of CRC from the American Cancer Society (ACS)
and the Center for Disease Control and Prevention (CDC) were also used. Transition
rates/probabilities were estimated from U.S. vital statistics and cancer statistics and from
published data on the sensitivity, specificity, and efficacy of various screening strategies.
Also, survival data was obtained from the report of the National Cancer Institute’s
Surveillance, Epidemiology, and End Results (SEER, 2004). A description of each
parameter, a baseline value, references for this value, and a range of values for sensitivity
analysis is included in Table 3-1.
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Table 3-1 – Variables Used in Decision Analysis Model
Variable

Value

Reference

pCancer

0.0025

Winawer 1997

pCancer_CRCHist

0.012

Winawer 1997

pCancer_CRCHist_ASA

0.008

pCancer_CRCHist_COX2

0.008

Winawer 1997, Ladabaum
2001
Winawer 1997, Steinbach 2000

pCancer_polyphist

0.003

Winawer 1997

pCancer_polyphist_ASA

0.002

Winawer 1997

pCancer_polyphist_COX2

0.002

Winawer 1997

pCancer_Well_Colon

0.0048

Winawer 1997

pCancer_Well_Colon_ASA

0.00336

Winawer 1997, Ladabaum 2001

pCancer_Well_Colon_COX2

0.003456

Winawer 1997, Steinbach 2000

pCancer_Well_FOBT

0.0135

Winawer 1997

pCancer_Well_FOBTFS

0.00956

Winawer 1997

pCancer_Well_FOBTFS_ASA

0.00672

Winawer 1997, Ladabaum 2001

pCancer_Well_FOBTFS_COX2

0.006912

Winawer 1997

pCancer_Well_FOBT_ASA

0.00945

Winawer 1997, Ladabaum 2001

pCancer_Well_FOBT_COX2

0.00972

Winawer 1997, Steinbach 2000

pCRCL_Well_FOBT

0.7

Winawer 1997

pLocal_Colon

0.67

Ladabaum 2001

pLocal_Colon_ASA

0.64

Ladabaum 2001

pLocal_Colon_COX2

0.66

Ladabaum 2003

pLocal_CRCHist

0.82

Brady 1990

0.7

Ladabaum 2001

pLocal_FOBT
pLocal_FOBTFS

0.735

Ladabaum 2001

pLocal_FOBTFS_ASA

0.69

Ladabaum 2001

pLocal_FOBTFS_COX2

0.735

Ladabaum 2003

pLocal_FOBT_ASA

0.66

Ladabaum 2001

pLocal_FOBT_COX2

0.7

Ladabaum 2003

pMetaCRC_Colon

0.118

Ladabaum 01

pMetaCRC_Colon_ASA

0.09

Ladabaum 01

pMetaCRC_Colon_COX2

0.12

Ladabaum 03

pMetaCRC_CRCHist

0.18

Brady 1990

pMetaCRC_FOBT

0.1

Ladabaum 01

pMetaCRC_FOBTFS

0.106

Ladabaum 01

pMetaCRC_FOBTFS_ASA

0.08

Ladabaum 01

pMetaCRC_FOBTFS_COX2

0.106

Ladabaum 03

pMetaCRC_FOBT_ASA

0.08

Ladabaum 01

pMetaCRC_FOBT_COX2

0.1

Ladabaum 03

pMetaCRC_Well_FOBT

0.1

Ladabaum 01

pNormal_CRCHist

0.91

pNormal_polyphist

0.824

pNormal_Well_Colon

0.74

Rex 95, Weber 86, Larson 86,
Kronberg 83, Juhl 90
Rex 95, Winawer 97, Nava 87,
McFarland 91, Jorgenson 93
Winawer 97

pNormal_Well_FOBTFS

0.72

Winawer 97

pNormal_Well_FOBT

0.99

Winawer 97

45

Table 3-1 – Variables Used in Decision Analysis Model, continued
pPolyp_CRCHist

0.05

pPolyp_CRCHist_ASA

0.035

McFarland 1991
McFarland 1991, Ladabaum
2001

pPolyp_CRCHist_COX2

0.036

McFarland 1991, Rahme 2003

pPolyp_polyphist

0.16

Winawer 97

pPolyp_polyphist_ASA

0.112

Winawer 97, Ladabaum 2001

pPolyp_polyphist_COX2

0.115

Winawer 97, Rahme 2003

pPolyp_Well_Colon

0.29

Winawer 97

pPolyp_Well_Colon_ASA

0.11991

Winawer 97, Ladabaum 2001

pPolyp_Well_Colon_COX2

0.123336

Winawer 97, Rahme 2003

pPolyp_Well_FOBT

0.347

Winawer 97

pPolyp_Well_FOBTFS

0.35

Winawer 97

pPolyp_Well_FOBTFS_ASA

0.14399

Winawer 97, Ladabaum 2001

pPolyp_Well_FOBTFS_COX2

0.148104

Winawer 97, Rahme 2003

pPolyp_Well_FOBT_ASA

0.14693

Winawer 97, Ladabaum 2001

pPolyp_Well_FOBT_COX2

0.151128

Winawer 97, Rahme 2003

pRecurrentCRC_CRCL

0.25

Colorectal Cancer Network

pRecurrentCRC_CRCR

0.6

Colorectal Cancer Network
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Utilities
Utilities are numerical values assigned to health states.

Utilities reflect the

desirability of existing in a given state. Utilities range from 0 to 1, with 1 representing
perfect health and 0 representing death. Utilities for each health state are multiplied by
the amount of time an individual spends in each state, and the results are added together
over the individual’s lifetime to obtain the estimated quality adjusted life years (QALYs).
Utility values for the different Markov states used in this model were derived from
published literature (Table 3-2). The utilities for local regional, and distant CRC were
taken from Ness and colleagues (Ness et al., 1999). These are the utility values for
individuals who have local, regional, and distant CRC. The utilities for individuals in the
states of well with polyp history, well with history of local CRC, and well with history of
regional CRC were estimated from the utilities in the Ness study.
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Table 3-2 – Utilities and their Corresponding Health States
uWell
uPolypHist
uWell_LocalHist
uWell_RegionalHist
uCRC_L
uCRC_R
uCRC_D
uDead
* Ness (1999)
** estimated from Ness (1999)

1
0.95**
0.87**
0.84**
0.74*
0.59*
0.25*
0
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3.4 Effectiveness and Costs
Quality adjusted life years (QALYs) were used as the primary outcome measure.
Costs were estimated from a societal perspective. The costs included were only direct
costs. Wagner and colleagues (Wagner et al., 1996) Frazier and colleagues (Frazier et al.,
2000), and Khandker and colleagues (Khandker et al., 2000) all included only direct costs
from a societal perspective. Costs included cost of screening, diagnostic procedures,
chemopreventive drugs, and costs for CRC treatment (localized, regional, and distant;
initial and incremental). These costs were derived from Frazier and colleagues (Frazier et
al., 2000) in which the costs were obtained from a large health maintenance organization
(Taplin et al., 1995). The costs of CRC treatment include the actual costs of medical
personnel and supplies to provide the service as well as overhead costs, such as
medication administration, charting, and utilization of automated information systems.
The costs of chemopreventive drugs were obtained using the average wholesale price
(Redbook, 2005).

All costs were updated to 2005 dollars using the medical care

component of the Consumer Price Index (Statistical Abstract of the United States, 2005).
Future health is often considered to be less valuable than immediate health. This was
accounted for in the model by discounting future utility by a constant rate. The baseline
discount rate in this model was 3%.
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Table 3-3 – Direct Costs of Colorectal Cancer Screening Procedures and
Chemopreventive Agents

Variable
cASA

Description
cost of 81mg of aspirin, 1 a day

18

cost of colonoscopy

cost of cyclooxygenas-2 inhibitor

cost of CRC Local

Initial cost of treating localized

21.6

975.5

1463.24

2712.19

4068.29

Ness 2000

NDA

NDA

Ness 2000

NDA

NDA

36.63

54.95

268.94

403.4

488.71

733.07

NDA

NDA

Redbook
Khandker 2000

3,390.24

Redbook, 2005

(425)

Initial cost of treating regionalized

18457

cancer (incremental)

(1944)

cost of fecal occult blood test

Frazier 2000, Wagner 1996,

cFOBT

45.79
cost of flexible sigmoidoscopy

Khandker 2000
Frazier 2000, Wagner 1996,

cFS

336.17

Khandker 2000

610.89

Frazier 2000, Wagner 1996,
Khandker 2000

21093

Ness 2000

cost of polypectomy
cPolypectomy
cost of CRC Distant

14.4

Reference

1,219.37

16052

cancer (incremental)
cost of CRC
Regional

High
Range
in dollars

Frazier 2000, Wagner 1996,

cColonoscopy

cCOX2

Low
Range
in dollars

Cost in
dollars

Initial cost of treating metastatic

cancer (incremental)

(21,209)

c = cost
NDA = No Data Available
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3.5 Outcome Measure
Cost per QALY was used as the outcome measure in this study. The QALY
combines quality of life with length of life by adjusting life-years with a quality weight,
measured as a utility. Costs per life-year saved is the outcome measure employed in the
cost-effectiveness studies used as references for this study. Currently, there is no costeffectiveness study analyzing the CRC screening procedures or chemopreventive agents
used in this study in which the outcome measure is QALY.

3.6 Base-case Cost-effectiveness Analysis
The base case analysis represents the overall cost and effectiveness associated
with each screening strategy. The costs and effectiveness obtained are then used to
calculate the incremental cost-effectiveness ratio (ICER) for each screening strategy. The
incremental analyses were performed by rank ordering the strategies by increasing cost
after eliminating those that were more costly and less effective than an alternative
strategy. In other words, those strategies that are more costly and less effective are ruled
out by simple dominance. The ICER (additional cost divided by additional benefit) for
each strategy was then calculated to compare with the next least expensive strategy.
Strategies with a lower effectiveness, and higher cost-effectiveness ratios than another
strategy, were ruled out by weak dominance and the ICER was then recalculated.
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3.6 Sensitivity Analysis
One-way sensitivity analyses were performed to assess the factors that have the
greatest effect on the cost-effectiveness of screening. In this case, the sensitivity analyses
were performed on all variables of interest in the model, including but not limited to
screening strategies, as well as utility, or disutility, associated with screening. The
analyses vary the variables over a range of values for each screening strategy to account
for reasonable values for uncertain parameters. For example, the base case probability of
developing localized cancer after an individual has previously been diagnosed and treated
successfully for cancer (pRecurrentCRC_CRCL) is 0.25. In the sensitivity analysis, the
range for pRecurrentCRC_CRCL is 0.1 to 0.4. The ranges of values for the sensitivity
analyses were based on parameter values used in selected studies. One such study was
conducted by the U.S. Congress, Office of Technology Assessment (OTA). This study
contains a summary of the specific assumptions about parameter values used in the
analysis and the range of reasonable values for particularly uncertain parameters. The
evidence for many of these assumptions is reviewed in OTA’s previous report (OTA,
1990).
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Table 3-4 – Variables used in Sensitivity Analysis, Base Value, and Low and High
Ranges
Variable Name
Base Value
Low Range
High Range
pCancer_Well_Colon_ASA
pCancer_Well_Colon_COX2
pCancer_Well_FOBTFS_ASA
pCancer_Well_FOBTFS_COX2
pCancer_Well_FOBT_ASA
pCancer_Well_FOBT_COX2
pNormal_CRCHist
pNormal_polyphist
pPolyp_Well_Colon_ASA
pPolyp_Well_Colon_COX2
pPolyp_Well_FOBTFS_ASA
pPolyp_Well_FOBTFS_COX2
pPolyp_Well_FOBT_ASA
pPolyp_Well_FOBT_COX2
pRecurrentCRC_CRCL
pRecurrentCRC_CRCR
cASA
cColonoscopy
cCOX2
cFOBT
cFS
cPolypectomy

0.00336
0.003456
0.00672
0.006912
0.00945
0.00972
0.91
0.824
0.11991
0.123336
0.14399
0.148104
0.14693
0.151128
0.25
0.6
18
1,219.37
3,390.24
45.79
336.17
610.89
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0.00312
0.003216
0.006214
0.006405
0.008775
0.009045
0.79
0.75
0.111345
0.114771
0.133705
0.137819
0.136435
0.140633
0.1
0.25
14.4
975.5
2712.19
36.63
268.94
488.71

0.0036
0.003696
0.00717
0.0073612
0.010125
0.010395
0.98
0.88
0.128475
0.131901
0.154275
0.162589
0.157425
0.161623
0.4
0.75
21.6
1463.24
4068.29
54.95
403.4
733.07

4. Results
This study involved the construction of a decision analysis model to outline the
costs and benefits associated with colorectal cancer (CRC) screening and the use of
chemopreventive agents. This section presents the results of total costs, total
effectiveness, and incremental cost-effectiveness ratios (ICER) of the different screening
strategies incorporated in the decision model.

4.1 Base Case Analysis Results
The decision model was constructed to evaluate the total costs and benefits of
nine CRC screening strategies (Figure 3-1). A hypothetical cohort of 100,000 averagerisk males was evaluated in the model. The base case results for cost, effectiveness and
the ICER for each of the nine screening strategies are reported in Table 4-1. These
results are also represented graphically in Figure 4-1.
The most cost-effective screening strategy was Fecal Occult Blood Test (FOBT);
followed by FOBT plus aspirin, colonoscopy, and colonoscopy plus aspirin. The ICER
of FOBT is $13,014.85 compared to Natural History. The ICER of FOBT plus aspirin,
the second most cost-effective strategy, is $7,173.35 when compared to FOBT. The
ICER of colonoscopy is $35.43. This signifies that colonoscopy and FOBT plus aspirin
are sensitive to changes in both cost and effectiveness. Small changes in either cost or
effectiveness may alter the cost-effectiveness ordering of these two strategies. The least
cost-effective strategies were those that utilized a COX-2 inhibitor as the
chemopreventive agent.
The ICER results show the dominance status of the screening strategies. The five
strategies at the bottom of Table 4-1 are all dominated by colonoscopy plus aspirin. This
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means that each of these strategies were more expensive and less effective than
colonoscopy plus aspirin.
Figure 4-1 shows the cost-effectiveness of all nine screening strategies. The
strategies toward the bottom of the graph were less expensive, while those to the right
side of the graph were the most effective. The strategies that are the most cost-effective
are represented in the bottom right quadrant of the graph. These include FOBT, FOBT
plus aspirin, and colonoscopy. Those that are the represented in the upper portion of the
graph represent the least cost-effective screening strategies. These include FOBT plus
COX-2, FOBT/FS plus COX-2, and Colonoscopy plus COX-2.
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Table 4-1: Base Case Results of Colorectal Cancer Screening Strategies and Chemopreventive Agents

Costs
(in U.S. dollars)

Effectiveness

Incremental Cost
Effectiveness Ratio

Natural History

188.02

16.8789

--

FOBT

2295.9

17.0409

13,014.95

FOBT plus ASA

2673.96

17.0936

7,173.55

Colonoscopy

2677.6

17.1965

35.43

Colonoscopy plus ASA

3003.21

17.2083

27,513.64

FOBT plus FS

3991.03

16.9322

Dominatedª

FOBT/FS plus ASA

4549.99

17.0091

Dominatedª

FOBT plus COX-2

62,388.23

17.0891

Dominatedª

FOBT/FS plus COX-2

64,210.65

17.0023

Dominatedª

Colonoscopy plus COX-2

62,810.35

17.2072

Dominatedª

Screening Strategy

FOBT = annual Fecal Occult Blood Test
FOBT/FS - annual Fecal Occult Blood Test and Flexible Sigmoidoscopy every five years
Colonoscopy - Colonoscopy every ten years
ASA - aspirin, 81 milligrams daily
COX-2 - Cyclooxygenase-2 Inhibitor, 425 milligrams daily
ªDominated by Colonoscopy plus ASA
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Figure 4-1 Cost-Effectiveness of Colorectal Cancer Screening and Chemoprevention
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4.2 Sensitivity Analysis

The estimates for the input parameters, both costs and effectiveness were derived
and integrated from multiple sources (Table 3-1 and Table 3-3). Thus, like any other
economic model, the present model contains a measure of uncertainty. Sensitivity
analysis is a commonly used tool to deal with uncertainty in the model input parameters.
In one-way sensitivity analyses, one parameter at a time is varied over a certain range and
the ICERs are re-calculated. A comparison between the original ICER and those
obtained from sensitivity analyses provide an indication of the stability of the model to
changes in the values of the parameter.

Effect of Changes in Cost of Screening Strategies
The impacts of changes in the cost of screening procedures are reported in Tables
4-2 through 4-5. The total costs the screening procedure were varied between plus and
minus 20% of the baseline estimates.
The strategies of FOBT/Flexible Sigmoidoscopy (FS), FOBT/FS plus ASA,
FOBT plus COX-2, colonoscopy plus COX-2, and FOBT/FS plus COX-2 all remained
dominated by the strategy of colonoscopy plus ASA within all changes in parameters of
cost. However, if the cost of FOBT was raised from $45.39 to $46.03 ($0.64 difference),
FOBT plus ASA would be dominated by colonoscopy. This is because colonoscopy is
not only more effective, but also less expensive. In addition, if the cost of colonoscopy
was reduced from $1,219.37 to $1,215.57 ($3.80 difference), FOBT plus ASA would
become dominated by colonoscopy (Table 4-4). This shows that the ICER is quite
sensitive to the cost of these two screening procedures. The base case cost of
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polypectomy in this model is $610.89. If the cost of polypectomy increased by
approximately $30 to $640.75, FOBT plus ASA will again become dominated by
colonoscopy (Table 4-5). The costs, effectiveness, and ICER results were not sensitive to
changes in the cost of FS (Table 4-3).
Overall, the cost-effectiveness order did not change other than FOBT plus aspirin
and colonoscopy when the above changes in cost parameters were made.
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Table 4-2: One Way Sensitivity Analyses Results of Colorectal Cancer Screening Strategies and Chemopreventive Agents
Parameter: Cost of Fecal Occult Blood Test

Base Case:
Screening Strategy

$45.79

Lower Range:

$36.63

Upper Range:

$54.95

Cost

Effectiveness

ICER

Cost

Effectiveness

ICER

Cost

Effectiveness

FOBT

$2,295.90

17.041

$13,014.95

$2,162.73

17.041

$12,192.71

$2,429.07

17.041

FOBT + ASA

$2,673.96

17.094

$7,173.55

$2,532.94

17.094

$7,024.68

$2,814.97

17.094

Colonoscopy

$2,677.60

17.196

$35.43

$2,677.60

17.196

$1,405.62

$2,677.60

17.196

$1,597.09

Colonoscopy + ASA

$3,003.21

17.208

$27,513.64

$3,003.21

17.208

$27,513.64

$3,003.21

17.208

$27,513.64

FOBT/FS

$3,991.03

16.932

(Dominated) ª

$3,875.01

16.932

(Dominated) ª

$4,107.05

16.932

(Dominated) ª

FOBT/FS + ASA

$4,549.99

17.009

(Dominated) ª

$4,422.31

17.009

(Dominated) ª

$4,677.68

17.009

(Dominated) ª

FOBT + COX-2

$62,388.23

17.089

(Dominated) ª

$62,247.76

17.089

(Dominated) ª

$62,528.70

17.089

(Dominated) ª

Colonoscopy + COX-2

$62,810.35

17.207

(Dominated) ª

$62,810.35

17.207

(Dominated) ª

$62,810.35

17.207

(Dominated) ª

FOBT/FS + COX-2

$64,210.65

17.002

(Dominated) ª

$64,083.79

17.002

(Dominated) ª

$64,337.51

17.002

(Dominated) ª

FOBT = annual Fecal Occult Blood Test
FOBT/FS - annual Fecal Occult Blood Test and Flexible Sigmoidoscopy every five years
Colonoscopy - Colonoscopy every ten years
ASA - aspirin, 81 milligrams daily
COX-2 - Cyclooxygenase-2 Inhibitor, 425 milligrams daily
ICER = Incremental Cost-Effectiveness Ratio
ªDominated by Colonoscopy plus ASA
Dominated by Colonoscopy

b
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ICER

$13,837.19
(Dominated)b

Table 4-3: One Way Sensitivity Analyses Results of Colorectal Cancer Screening Strategies and Chemopreventive Agents
Parameter: Cost of Flexible Sigmoidoscopy

Base Case:
Screening Strategy

$336.17

Lower Range:

$268.94

Upper Range:

$403.40

Cost

Effectiveness

ICER

Cost

Effectiveness

ICER

Cost

Effectiveness

ICER

FOBT

$2,295.90

17.041

$13,014.95

$2,295.90

17.041

$13,014.95

$2,295.90

17.041

$13,014.95

FOBT + ASA

$2,673.96

17.094

$7,173.55

$2,673.96

17.094

$7,173.55

$2,673.96

17.094

$7,173.55

Colonoscopy

$2,677.60

17.196

$35.43

$2,677.60

17.196

$35.43

$2,677.60

17.196

$35.43

Colonoscopy + ASA

$3,003.21

17.208

$27,513.64

$3,003.21

17.208

$27,513.64

$3,003.21

17.208

$27,513.64

FOBT/FS

$3,991.03

16.932

(Dominated)ª

$3,807.26

16.932

(Dominated)ª

$4,174.80

16.932

(Dominated)ª

FOBT/FS + ASA

$4,549.99

17.009

(Dominated)ª

$4,351.90

17.009

(Dominated)ª

$4,748.09

17.009

(Dominated)ª

FOBT + COX-2

$62,388.23

17.089

(Dominated)ª

$62,388.23

17.089

(Dominated)ª

$62,388.23

17.089

(Dominated)ª

Colonoscopy + COX-2

$62,810.35

17.207

(Dominated)ª

$62,810.35

17.207

(Dominated)ª

$62,810.35

17.207

(Dominated)ª

FOBT/FS + COX-2

$64,210.65

17.002

(Dominated)ª

$64,013.57

17.002

(Dominated)ª

$64,407.73

17.002

(Dominated)ª

FOBT = annual Fecal Occult Blood Test
FOBT/FS - annual Fecal Occult Blood Test and Flexible Sigmoidoscopy every five years
Colonoscopy - Colonoscopy every ten years
ASA - aspirin, 81 milligrams daily
COX-2 - Cyclooxygenase-2 Inhibitor, 425 milligrams daily
ICER = Incremental Cost-Effectiveness Ratio
ªDominated by Colonoscopy plus ASA
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Table 4-4: One Way Sensitivity Analyses Results of Colorectal Cancer Screening Strategies and Chemopreventive Agents
Parameter: Cost of Colonoscopy

Base Case:
Screening Strategy

$1,219.37

Lower Range:

$975.50

Cost

Effectiveness

ICER

Cost

Effectiveness

FOBT

$2,295.84

17.041

$13,014.60

$2,015.29

17.041

FOBT + ASA

$2,673.89

17.094

$7,173.49

$2,377.09

17.094

Colonoscopy

$2,677.49

17.196

$34.97

$2,150.40

17.196

Colonoscopy + ASA

$3,003.10

17.208

$27,513.58

$2,472.37

FOBT/FS

$3,990.94

16.932

(Dominated)

FOBT/FS + ASA

$4,549.90

17.009

(Dominated)

FOBT + COX-2

$62,388.17

17.089

Colonoscopy + COX-2

$62,810.25

FOBT/FS + COX-2

$64,210.55

Upper Range:

$1,463.24

ICER

Cost

Effectiveness

ICER

$11,282.37

$2,576.39

17.041

$14,746.82

$2,970.69

17.094

$7,481.83

$868.20

$3,204.59

17.196

$2,272.67

17.208

$27,205.93

$3,533.84

17.208

$27,821.22

$3,559.39

16.932

(Dominated)

$4,422.50

16.932

(Dominated)

$4,079.54

17.009

(Dominated)

$5,020.25

17.009

(Dominated)

(Dominated)

$62,092.49

17.089

(Dominated)

$62,683.84

17.089

(Dominated)

17.207

(Dominated)

$62,279.76

17.207

(Dominated)

$63,340.73

17.207

(Dominated)

17.002

(Dominated)

$63,742.94

17.002

(Dominated)

$64,678.16

17.002

(Dominated)

FOBT = annual Fecal Occult Blood Test
FOBT/FS - annual Fecal Occult Blood Test and Flexible Sigmoidoscopy every five years
Colonoscopy - Colonoscopy every ten years
ASA - aspirin, 81 milligrams daily
COX-2 - Cyclooxygenase-2 Inhibitor, 425 milligrams daily
ICER = Incremental Cost-Effectiveness Ratio
ªDominated by Colonoscopy plus ASA
Dominated by Colonoscopy

b
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(Dominated)b

Table 4-5: One Way Sensitivity Analyses Results of Colorectal Cancer Screening Strategies and Chemopreventive Agents
Parameter: Cost of Polypectomy

Base Case:
Screening Strategy

$610.89

Lower Range:

$488.71

Upper Range:

$733.07

Cost

Effectiveness

ICER

Cost

Effectiveness

ICER

Cost

Effectiveness

FOBT

$2,295.90

17.041

$13,014.95

$2,266.40

17.041

$12,832.82

$2,325.40

17.041

FOBT + ASA

$2,673.96

17.094

$7,173.55

$2,652.11

17.094

$7,318.77

$2,695.80

17.094

Colonoscopy

$2,677.60

17.196

$35.43

$2,670.68

17.196

$180.44

$2,684.52

17.196

$2,307.75

Colonoscopy + ASA

$3,003.21

17.208

$27,513.64

$2,998.34

17.208

$27,686.23

$3,008.09

17.208

$27,341.06

FOBT/FS

$3,991.03

16.932

(Dominated) ª

$3,946.05

16.932

(Dominated) ª

$4,036.01

16.932

(Dominated) ª

FOBT/FS + ASA

$4,549.99

17.009

(Dominated) ª

$4,515.67

17.009

(Dominated) ª

$4,584.31

17.009

(Dominated) ª

FOBT + COX-2

$62,388.23

17.089

(Dominated) ª

$62,365.84

17.089

(Dominated) ª

$62,410.61

17.089

(Dominated) ª

Colonoscopy + COX-2

$62,810.35

17.207

(Dominated) ª

$62,805.34

17.207

(Dominated) ª

$62,815.37

17.207

(Dominated) ª

FOBT/FS + COX-2

$64,210.65

17.002

(Dominated) ª

$64,175.55

17.002

(Dominated) ª

$64,245.74

17.002

(Dominated) ª

FOBT = annual Fecal Occult Blood Test
FOBT/FS - annual Fecal Occult Blood Test and Flexible Sigmoidoscopy every five years
Colonoscopy - Colonoscopy every ten years
ASA - aspirin, 81 milligrams daily
COX-2 - Cyclooxygenase-2 Inhibitor, 425 milligrams daily
ICER = Incremental Cost-Effectiveness Ratio
ªDominated by Colonoscopy plus ASA
Dominated by Colonoscopy

b
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ICER

$13,197.08
(Dominated)b

Effect of Changes in Cost of Chemopreventive Agents
The impact of changes in the cost of chemopreventive agents is reported in Tables
4-6 and 4-7. The total costs of the chemopreventive agents were varied between plus
20% and minus 20% of the baseline estimates.
Similar to the sensitivity analyses for the costs of screening strategies, when the costs of
chemopreventive agents are varied four strategies remain as cost-effective. Those
strategies are FOBT, FOBT plus ASA, Colonoscopy and Colonoscopy plus ASA. The
base case cost of aspirin is $18 per year. If this cost increased to $18.21, FOBT plus
aspirin would become dominated by colonoscopy. This minor change in the cost of
aspirin shows that the ICER of FOBT plus aspirin and colonoscopy are quite sensitive to
this cost.
The cost of a cycooxygenase-2 (COX-2) inhibitor is prohibitive with regard to
cost-effectiveness. Although the screening strategies that include a COX-2 inhibitor have
the greatest effectiveness, the costs are disproportionately high. The base case cost of
COX-2 inhibitor in this model is $3,390.24 per year. The cost of COX-2 inhibitor was
varied by plus and minus 20% of the base-case estimate. No changes occurred; therefore
the cost of COX-2 inhibition is not sensitive in the 20% range. Only if the cost of a
COX-2 inhibitor was reduced to below $92.40 would the cost not be prohibitive. At this
cost, FOBT plus COX-2 inhibition would have higher effectiveness and lower costs than
FOBT/FS. Additionally, the cost of a COX-2 inhibitor would have to be lower than the
cost of aspirin to be more cost-effective than any strategy utilizing aspirin as the
chemopreventive agent.
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Table 4-6: One Way Sensitivity Analyses Results of Colorectal Cancer Screening Strategies and Chemopreventive Agents
Parameter: Cost of Aspirin

Base Case:
Screening Strategy

$18.00

Lower Range:

$14.40

Upper Range:

$21.60

Cost

Effectiveness

ICER

Cost

Effectiveness

ICER

Cost

Effectiveness

FOBT

$2,295.90

17.041

$13,014.95

$2,295.90

17.041

$13,014.95

$2,295.90

17.041

FOBT + ASA

$2,673.96

17.094

$7,173.55

$2,610.20

17.094

$5,963.84

$2,737.71

17.094

Colonoscopy

$2,677.60

17.196

$35.43

$2,677.60

17.196

$654.90

$2,677.60

17.196

$2,452.83

Colonoscopy + ASA

$3,003.21

17.208

$27,513.64

$2,939.37

17.208

$22,118.66

$3,067.06

17.208

$32,908.62

FOBT/FS

$3,991.03

16.932

(Dominated) ª

$3,991.03

16.932

(Dominated) ª

$3,991.03

16.932

(Dominated) ª

FOBT/FS + ASA

$4,549.99

17.009

(Dominated) ª

$4,486.28

17.009

(Dominated) ª

$4,613.70

17.009

(Dominated) ª

FOBT + COX-2

$62,388.23

17.089

(Dominated) ª

$62,388.23

17.089

(Dominated) ª

$62,388.23

17.089

(Dominated) ª

Colonoscopy + COX-2

$62,810.35

17.207

(Dominated) ª

$62,810.35

17.207

(Dominated) ª

$62,810.35

17.207

(Dominated) ª

FOBT/FS + COX-2

$64,210.65

17.002

(Dominated) ª

$64,210.65

17.002

(Dominated) ª

$64,210.65

17.002

(Dominated) ª

FOBT = annual Fecal Occult Blood Test
FOBT/FS - annual Fecal Occult Blood Test and Flexible Sigmoidoscopy every five years
Colonoscopy - Colonoscopy every ten years
ASA - aspirin, 81 milligrams daily
COX-2 - Cyclooxygenase-2 Inhibitor, 425 milligrams daily
ICER = Incremental Cost-Effectiveness Ratio
ªDominated by Colonoscopy plus ASA
Dominated by Colonoscopy

b
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ICER

$13,014.95
(Dominated)b

Table 4-7: One Way Sensitivity Analyses Results of Colorectal Cancer Screening Strategies and Chemopreventive Agents
Parameter: Cost of Cyclooxygenase-2 Inhibitor

Base Case:
Screening Strategy

$3,390.24

Lower Range:

$2,712.19

Upper Range:

$4,068.29

Cost

Effectiveness

ICER

Cost

Effectiveness

ICER

Cost

Effectiveness

ICER

FOBT

$2,295.90

17.041

$13,014.95

$2,295.90

17.041

$13,014.95

$2,295.90

17.041

$13,014.95

FOBT + ASA

$2,673.96

17.094

$7,173.55

$2,673.96

17.094

$7,173.55

$2,673.96

17.094

$7,173.55

Colonoscopy

$2,677.60

17.196

$35.43

$2,677.60

17.196

$35.43

$2,677.60

17.196

$35.43

Colonoscopy + ASA

$3,003.21

17.208

$27,513.64

$3,003.21

17.208

$27,513.64

$3,003.21

17.208

$27,513.64

FOBT/FS

$3,991.03

16.932

(Dominated) ª

$3,991.03

16.932

(Dominated) ª

$3,991.03

16.932

(Dominated) ª

FOBT/FS + ASA

$4,549.99

17.009

(Dominated) ª

$4,549.99

17.009

(Dominated) ª

$4,549.99

17.009

(Dominated) ª

FOBT + COX-2

$62,388.23

17.089

(Dominated) ª

$50,381.54

17.089

(Dominated) ª

$74,394.91

17.089

(Dominated) ª

Colonoscopy + COX-2

$62,810.35

17.207

(Dominated) ª

$50,785.15

17.207

(Dominated) ª

$74,835.55

17.207

(Dominated) ª

FOBT/FS + COX-2

$64,210.65

17.002

(Dominated) ª

$52,212.63

17.002

(Dominated) ª

$76,208.66

17.002

(Dominated) ª

FOBT = annual Fecal Occult Blood Test
FOBT/FS - annual Fecal Occult Blood Test and Flexible Sigmoidoscopy every five years
Colonoscopy - Colonoscopy every ten years
ASA - aspirin, 81 milligrams daily
COX-2 - Cyclooxygenase-2 Inhibitor, 425 milligrams daily
ICER = Incremental Cost-Effectiveness Ratio
ªDominated by Colonoscopy plus ASA
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Effects of Changes in Probabilities

pNormal
The values of pNormal_CRCHist (Table 4-8) and pNormal_polyphist (Table 4-9)
were varied over ranges specified in Table 3-1. These variables represent the probability
of having a normal colonoscopy after having had a history of CRC and after having a
history of polyps, respectively. When varied over the specified ranges, these two
variables did not have any effect on the cost-effectiveness of the screening strategies, and
the dominance status remained the same.

pRecurrentCRC
The variables pRecurrentCRC_CRCL (Table 4-10) and pRecurrentCRC_CRCR
(Table 4-11) represent the probabilities of developing cancer after one has previously
been diagnosed and treated successfully for cancer (local and regional, respectively).
When varied over the specified ranges, these two variables had no effect on the costeffectiveness of the screening strategies, and the dominance status remained the same.

pPolyp_Well
The variable pPolyp_Well represents the probability of have a polyp found after
an abnormal screening test while the individual is in the Well state. The variables
included in the one-way sensitivity analysis with the “pPolyp_Well” prefix included
1) pPolyp_Well_FOBT_ASA

(Table 4-12)

2) pPolyp_Well_FOBT_COX2

(Table 4-13)
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3) pPolyp_Well_FOBTFS_ASA

(Table 4-14)

4) pPolyp_Well_FOBTFS_COX2 (Table 4-15)
5) pPolyp_Well_Colon_ASA

(Table 4-16)

6) pPolyp_Well_Colon_COX2

(Table 4-17)

These six variables were varied over the ranges specified in Table 3-1. In the sensitivity
analysis for pPolyp_Well_FOBT_ASA (Table 4-12), the variable (base-case 0.14693)
was ranged from (0.136435) to (0.157425). When the probability of having a polyp
detected after an abnormal screening test is lowered, the screening strategy FOBT plus
aspirin becomes dominated by colonoscopy because the cost of FOBT plus aspirin
exceeds the cost of colonoscopy, and the effectiveness remains lower.
In the sensitivity analysis for pPolyp_Well_Colon_ASA (Table 4-16), the
screening strategy FOBT/FS plus Cox-2 becomes dominated by colonoscopy plus Cox-2
when the probability of detection of a polyp for colonoscopy plus aspirin is increased. In
addition, when the probability of pPolyp_Well_Colon_COX2 (Table 4-17) is lowered to
the lower range, the screening strategy FOBT/FS plus COX-2 becomes dominated by
colonoscopy plus COX-2. This is due to the fact that the effectiveness of colonoscopy
plus COX-2 slightly increases from baseline.

pCancer_Well
The variable pCancer_Well represents the probability of having cancer found
after an abnormal screening test while the individual is in the Well state. The variables
included in the one-way sensitivity analysis with the “pCancer_Well” prefix (Table 4-18
to Table 23) included:
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1) pCancer_Well_FOBT_ASA

(Table 4-18)

2) pCancer_Well_FOBT_COX2

(Table 4-19)

3) pCancer_Well_FOBTFS_ASA

(Table 4-20)

4) pCancer_Well_FOBTFS_COX2 (Table 4-21)
5) pCancer_Well_Colon_ASA

(Table 4-22)

6) pCancer_Well_Colon_COX2

(Table 4-23)

When varied over the specified ranges in Table 3-1, these six variables had no effect on
the cost-effectiveness of the screening strategies, and the dominance status remained the
same.
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Table 4-8: One Way Sensitivity Analyses Results of Colorectal Cancer Screening Strategies and Chemopreventive Agents
Parameter: pNormal_CRCHist

Base Case:
Screening Strategy

0.91

Lower Range:

0.79

Upper Range:

0.98

Cost

Effectiveness

ICER

Cost

Effectiveness

ICER

Cost

Effectiveness

ICER

FOBT

$2,295.90

17.041

$13,014.95

$2,295.90

17.041

$13,014.95

$2,295.90

17.041

$13,014.95

FOBT + ASA

$2,673.96

17.094

$7,173.55

$2,673.96

17.094

$7,173.55

$2,673.96

17.094

$7,173.55

Colonoscopy

$2,677.60

17.196

$35.43

$2,677.60

17.196

$35.43

$2,677.60

17.196

$35.43

Colonoscopy + ASA

$3,003.21

17.208

$27,513.64

$3,003.21

17.208

$27,513.64

$3,003.21

17.208

$27,513.64

FOBT/FS

$3,991.03

16.932

(Dominated) ª

$3,991.03

16.932

(Dominated) ª

$3,991.03

16.932

(Dominated) ª

FOBT/FS + ASA

$4,549.99

17.009

(Dominated) ª

$4,549.99

17.009

(Dominated) ª

$4,549.99

17.009

(Dominated) ª

FOBT + COX-2

$62,388.23

17.089

(Dominated) ª

$62,388.23

17.089

(Dominated) ª

$62,388.23

17.089

(Dominated) ª

Colonoscopy + COX-2

$62,810.35

17.207

(Dominated) ª

$62,810.35

17.207

(Dominated) ª

$62,810.35

17.207

(Dominated) ª

FOBT/FS + COX-2

$64,210.65

17.002

(Dominated) ª

$64,210.65

17.002

(Dominated) ª

$64,210.65

17.002

(Dominated) ª

FOBT = annual Fecal Occult Blood Test
FOBT/FS - annual Fecal Occult Blood Test and Flexible Sigmoidoscopy every five years
Colonoscopy - Colonoscopy every ten years
ASA - aspirin, 81 milligrams daily
COX-2 - Cyclooxygenase-2 Inhibitor, 425 milligrams daily
ICER = Incremental Cost-Effectiveness Ratio
ªDominated by Colonoscopy plus ASA
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Table 4-9 One Way Sensitivity Analyses Results of Colorectal Cancer Screening Strategies and Chemopreventive Agents
Parameter: pNormal_polyphist

Base Case:
Screening Strategy

0.824

Lower Range:

0.75

Upper Range: 0.88

Cost

Effectiveness

ICER

Cost

Effectiveness

ICER

Cost

Effectiveness

ICER

FOBT

$2,295.90

17.041

$13,014.95

$2,295.90

17.041

$13,014.95

$2,295.90

17.041

$13,014.95

FOBT + ASA

$2,673.96

17.094

$7,173.55

$2,673.96

17.094

$7,173.55

$2,673.96

17.094

$7,173.55

Colonoscopy

$2,677.60

17.196

$35.43

$2,677.60

17.196

$35.43

$2,677.60

17.196

$35.43

Colonoscopy + ASA

$3,003.21

17.208

$27,513.64

$3,003.21

17.208

$27,513.64

$3,003.21

17.208

$27,513.64

FOBT/FS

$3,991.03

16.932

(Dominated) ª

$3,991.03

16.932

(Dominated) ª

$3,991.03

16.932

(Dominated) ª

FOBT/FS + ASA

$4,549.99

17.009

(Dominated) ª

$4,549.99

17.009

(Dominated) ª

$4,549.99

17.009

(Dominated) ª

FOBT + COX-2

$62,388.23

17.089

(Dominated) ª

$62,388.23

17.089

(Dominated) ª

$62,388.23

17.089

(Dominated) ª

Colonoscopy + COX-2

$62,810.35

17.207

(Dominated) ª

$62,810.35

17.207

(Dominated) ª

$62,810.35

17.207

(Dominated) ª

FOBT/FS + COX-2

$64,210.65

17.002

(Dominated) ª

$64,210.65

17.002

(Dominated) ª

$64,210.65

17.002

(Dominated) ª

FOBT = annual Fecal Occult Blood Test
FOBT/FS - annual Fecal Occult Blood Test and Flexible Sigmoidoscopy every five years
Colonoscopy - Colonoscopy every ten years
ASA - aspirin, 81 milligrams daily
COX-2 - Cyclooxygenase-2 Inhibitor, 425 milligrams daily
ICER = Incremental Cost-Effectiveness Ratio
ªDominated by Colonoscopy plus ASA
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Table 4-10: One Way Sensitivity Analyses Results of Colorectal Cancer Screening Strategies and Chemopreventive Agents
Parameter: pRecurrentCRC_CRCL

Base Case:
Screening Strategy

0.25

Lower Range:

0.1

Upper Range:

0.4

Cost

Effectiveness

ICER

Cost

Effectiveness

ICER

Cost

Effectiveness

ICER

FOBT

$2,295.90

17.041

$13,014.95

$2,295.90

17.041

$13,014.95

$2,295.90

17.041

$13,014.95

FOBT + ASA

$2,673.96

17.094

$7,173.55

$2,673.96

17.094

$7,173.55

$2,673.96

17.094

$7,173.55

Colonoscopy

$2,677.60

17.196

$35.43

$2,677.60

17.196

$35.43

$2,677.60

17.196

$35.43

Colonoscopy + ASA

$3,003.21

17.208

$27,513.64

$3,003.21

17.208

$27,513.64

$3,003.21

17.208

$27,513.64

FOBT/FS

$3,991.03

16.932

(Dominated) ª

$3,991.03

16.932

(Dominated) ª

$3,991.03

16.932

(Dominated) ª

FOBT/FS + ASA

$4,549.99

17.009

(Dominated) ª

$4,549.99

17.009

(Dominated) ª

$4,549.99

17.009

(Dominated) ª

FOBT + COX-2

$62,388.23

17.089

(Dominated) ª

$62,388.23

17.089

(Dominated) ª

$62,388.23

17.089

(Dominated) ª

Colonoscopy + COX-2

$62,810.35

17.207

(Dominated) ª

$62,810.35

17.207

(Dominated) ª

$62,810.35

17.207

(Dominated) ª

FOBT/FS + COX-2

$64,210.65

17.002

(Dominated) ª

$64,210.65

17.002

(Dominated) ª

$64,210.65

17.002

(Dominated) ª

FOBT = annual Fecal Occult Blood Test
FOBT/FS - annual Fecal Occult Blood Test and Flexible Sigmoidoscopy every five years
Colonoscopy - Colonoscopy every ten years
ASA - aspirin, 81 milligrams daily
COX-2 - Cyclooxygenase-2 Inhibitor, 425 milligrams daily
ICER = Incremental Cost-Effectiveness Ratio
ªDominated by Colonoscopy plus ASA
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Table 4-11: One Way Sensitivity Analyses Results of Colorectal Cancer Screening Strategies and Chemopreventive Agents
Parameter: pRecurrentCRC_CRCR

Base Case:
Screening Strategy

0.6

Lower Range:

0.25

Upper Range:

0.75

Cost

Effectiveness

ICER

Cost

Effectiveness

ICER

Cost

Effectiveness

ICER

FOBT

$2,295.90

17.041

$13,014.95

$2,295.90

17.041

$13,014.95

$2,295.90

17.041

$13,014.95

FOBT + ASA

$2,673.96

17.094

$7,173.55

$2,673.96

17.094

$7,173.55

$2,673.96

17.094

$7,173.55

Colonoscopy

$2,677.60

17.196

$35.43

$2,677.60

17.196

$35.43

$2,677.60

17.196

$35.43

Colonoscopy + ASA

$3,003.21

17.208

$27,513.64

$3,003.21

17.208

$27,513.64

$3,003.21

17.208

$27,513.64

FOBT/FS

$3,991.03

16.932

(Dominated) ª

$3,991.03

16.932

(Dominated) ª

$3,991.03

16.932

(Dominated) ª

FOBT/FS + ASA

$4,549.99

17.009

(Dominated) ª

$4,549.99

17.009

(Dominated) ª

$4,549.99

17.009

(Dominated) ª

FOBT + COX-2

$62,388.23

17.089

(Dominated) ª

$62,388.23

17.089

(Dominated) ª

$62,388.23

17.089

(Dominated) ª

Colonoscopy + COX-2

$62,810.35

17.207

(Dominated) ª

$62,810.35

17.207

(Dominated) ª

$62,810.35

17.207

(Dominated) ª

FOBT/FS + COX-2

$64,210.65

17.002

(Dominated) ª

$64,210.65

17.002

(Dominated) ª

$64,210.65

17.002

(Dominated) ª

FOBT = annual Fecal Occult Blood Test
FOBT/FS - annual Fecal Occult Blood Test and Flexible Sigmoidoscopy every five years
Colonoscopy - Colonoscopy every ten years
ASA - aspirin, 81 milligrams daily
COX-2 - Cyclooxygenase-2 Inhibitor, 425 milligrams daily
ICER = Incremental Cost-Effectiveness Ratio
ªDominated by Colonoscopy plus ASA
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Table 4-12: One Way Sensitivity Analyses Results of Colorectal Cancer Screening Strategies and Chemopreventive Agents
Parameter: pPolyp_Well_FOBT_ASA

Base Case:
Screening Strategy

0.14693

Lower Range:

0.136435

Cost

Effectiveness

ICER

Cost

Effectiveness

FOBT

$2,295.90

17.041

$13,014.95

$2,295.90

FOBT + ASA

$2,673.96

17.094

$7,173.55

$2,688.22

Colonoscopy

$2,677.60

17.196

$35.43

Colonoscopy + ASA

$3,003.21

17.208

FOBT/FS

$3,991.03

FOBT/FS + ASA

$4,549.99

FOBT + COX-2

Upper Range:

0.157425

ICER

Cost

Effectiveness

ICER

17.041

$13,014.95

$2,295.90

17.041

$13,014.95

17.1

(Dominated)b

$2,659.86

17.087

$7,872.56

$2,677.60

17.196

$2,452.83

$2,677.60

17.196

$162.19

$27,513.64

$3,003.21

17.208

$27,513.64

$3,003.21

17.208

$27,513.64

16.932

(Dominated) ª

$3,991.03

16.932

(Dominated) ª

$3,991.03

16.932

(Dominated) ª

17.009

(Dominated) ª

$4,577.79

17.015

(Dominated) ª

$4,522.55

17.004

(Dominated) ª

$62,388.23

17.089

(Dominated) ª

$62,388.23

17.089

(Dominated) ª

$62,388.23

17.089

(Dominated) ª

Colonoscopy + COX-2

$62,810.35

17.207

(Dominated) ª

$62,810.35

17.207

(Dominated) ª

$62,810.35

17.207

(Dominated) ª

FOBT/FS + COX-2

$64,210.65

17.002

(Dominated) ª

$64,210.65

17.002

(Dominated) ª

$64,210.65

17.002

(Dominated) ª

FOBT = annual Fecal Occult Blood Test
FOBT/FS - annual Fecal Occult Blood Test and Flexible Sigmoidoscopy every five years
Colonoscopy - Colonoscopy every ten years
ASA - aspirin, 81 milligrams daily
COX-2 - Cyclooxygenase-2 Inhibitor, 425 milligrams daily
ICER = Incremental Cost-Effectiveness Ratio
ªDominated by Colonoscopy plus ASA
Dominated by Colonoscopy

b
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Table 4-13: One Way Sensitivity Analyses Results of Colorectal Cancer Screening Strategies and Chemopreventive Agents
Parameter: pPolyp_Well_FOBT_COX2

Base Case:
Screening Strategy

0.151128

Lower Range:

0.140633

Upper Range:

0.161623

Cost

Effectiveness

ICER

Cost

Effectiveness

ICER

Cost

Effectiveness

ICER

FOBT

$2,295.90

17.041

$13,014.95

$2,295.90

17.041

$13,014.95

$2,295.90

17.041

$13,014.95

FOBT + ASA

$2,673.96

17.094

$7,173.55

$2,673.96

17.094

$7,173.55

$2,673.96

17.094

$7,173.55

Colonoscopy

$2,677.60

17.196

$35.43

$2,677.60

17.196

$35.43

$2,677.60

17.196

$35.43

Colonoscopy + ASA

$3,003.21

17.208

$27,513.64

$3,003.21

17.208

$27,513.64

$3,003.21

17.208

$27,513.64

FOBT/FS

$3,991.03

16.932

(Dominated) ª

$3,991.03

16.932

(Dominated) ª

$3,991.03

16.932

(Dominated) ª

FOBT/FS + ASA

$4,549.99

17.009

(Dominated) ª

$4,549.99

17.009

(Dominated) ª

$4,549.99

17.009

(Dominated) ª

FOBT + COX-2

$62,388.23

17.089

(Dominated) ª

$62,400.43

17.096

(Dominated) ª

$62,388.23

17.089

(Dominated) ª

Colonoscopy + COX-2

$62,810.35

17.207

(Dominated) ª

$62,810.35

17.207

(Dominated) ª

$62,810.35

17.207

(Dominated) ª

FOBT/FS + COX-2

$64,210.65

17.002

(Dominated) ª

$64,236.11

17.008

(Dominated) ª

$64,210.65

17.002

(Dominated) ª

FOBT = annual Fecal Occult Blood Test
FOBT/FS - annual Fecal Occult Blood Test and Flexible Sigmoidoscopy every five years
Colonoscopy - Colonoscopy every ten years
ASA - aspirin, 81 milligrams daily
COX-2 - Cyclooxygenase-2 Inhibitor, 425 milligrams daily
ICER = Incremental Cost-Effectiveness Ratio
ªDominated by Colonoscopy plus ASA
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Table 4-14: One Way Sensitivity Analyses Results of Colorectal Cancer Screening Strategies and Chemopreventive Agents
Parameter: pPolyp_Well_FOBTFS_ASA

Base Case:
Screening Strategy

0.14399

Lower Range:

0.133705

Upper Range:

0.154275

Cost

Effectiveness

ICER

Cost

Effectiveness

ICER

Cost

Effectiveness

ICER

FOBT

$2,295.90

17.041

$13,014.95

$2,295.90

17.041

$13,014.95

2,295.90

17.041

$13,014.95

FOBT + ASA

$2,673.96

17.094

$7,173.55

$2,673.96

17.094

$7,173.55

2,673.96

17.094

$7,173.55

Colonoscopy

$2,677.60

17.196

$35.43

$2,677.60

17.196

$35.43

2,677.60

17.196

$35.43

Colonoscopy + ASA

$3,003.21

17.208

$27,513.64

$3,003.21

17.208

$27,513.64

3,003.21

17.208

$27,513.64

FOBT/FS

$3,991.03

16.932

(Dominated) ª

$3,991.03

16.932

(Dominated) ª

3,991.03

16.932

(Dominated) ª

FOBT/FS + ASA

$4,549.99

17.009

(Dominated) ª

$4,569.52

17.013

(Dominated) ª

4,530.59

17.005

(Dominated) ª

FOBT + COX-2

$62,388.23

17.089

(Dominated) ª

$62,388.23

17.089

(Dominated) ª

62,388.23

17.089

(Dominated) ª

Colonoscopy + COX-2

$62,810.35

17.207

(Dominated) ª

$62,810.35

17.207

(Dominated) ª

62,810.35

17.207

(Dominated) ª

FOBT/FS + COX-2

$64,210.65

17.002

(Dominated) ª

$64,210.65

17.002

(Dominated) ª

64,210.65

17.002

(Dominated) ª

FOBT = annual Fecal Occult Blood Test
FOBT/FS - annual Fecal Occult Blood Test and Flexible Sigmoidoscopy every five years
Colonoscopy - Colonoscopy every ten years
ASA - aspirin, 81 milligrams daily
COX-2 - Cyclooxygenase-2 Inhibitor, 425 milligrams daily
ICER = Incremental Cost-Effectiveness Ratio
ªDominated by Colonoscopy plus ASA
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Table 4-15: One Way Sensitivity Analyses Results of Colorectal Cancer Screening Strategies and Chemopreventive Agents
Parameter: pPolyp_Well_FOBTFS_COX2

Base Case:
Screening Strategy

0.148104

Lower Range:

0.137819

Upper Range:

0.162589

Cost

Effectiveness

ICER

Cost

Effectiveness

ICER

Cost

Effectiveness

ICER

FOBT

$2,295.90

17.041

$13,014.95

$2,295.90

17.041

$13,014.95

$2,295.90

17.041

$13,014.95

FOBT + ASA

$2,673.96

17.094

$7,173.55

$2,673.96

17.094

$7,173.55

$2,673.96

17.094

$7,173.55

Colonoscopy

$2,677.60

17.196

$35.43

$2,677.60

17.196

$35.43

$2,677.60

17.196

$35.43

Colonoscopy + ASA

$3,003.21

17.208

$27,513.64

$3,003.21

17.208

$27,513.64

$3,003.21

17.208

$27,513.64

FOBT/FS

$3,991.03

16.932

(Dominated) ª

$3,991.03

16.932

(Dominated) ª

$3,991.03

16.932

(Dominated) ª

FOBT/FS + ASA

$4,549.99

17.009

(Dominated) ª

$4,549.99

17.009

(Dominated) ª

$4,549.99

17.009

(Dominated) ª

FOBT + COX-2

$62,388.23

17.089

(Dominated) ª

$62,388.23

17.089

(Dominated) ª

$62,388.23

17.089

(Dominated) ª

Colonoscopy + COX-2

$62,810.35

17.207

(Dominated) ª

$62,810.35

17.207

(Dominated) ª

$62,810.35

17.207

(Dominated) ª

FOBT/FS + COX-2

$64,206.97

17.001

(Dominated) ª

$64,228.72

17.007

(Dominated) ª

$64,185.38

16.996

(Dominated) ª

FOBT = annual Fecal Occult Blood Test
FOBT/FS - annual Fecal Occult Blood Test and Flexible Sigmoidoscopy every five years
Colonoscopy - Colonoscopy every ten years
ASA - aspirin, 81 milligrams daily
COX-2 - Cyclooxygenase-2 Inhibitor, 425 milligrams daily
ICER = Incremental Cost-Effectiveness Ratio
ªDominated by Colonoscopy plus ASA
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Table 4-16: One Way Sensitivity Analyses Results of Colorectal Cancer Screening Strategies and Chemopreventive Agents
Parameter: pPolyp_Well_Colonoscopy_ASA

Base Case:
Screening Strategy

0.11991

Lower Range:

0.111345

Upper Range:

0.128475

Cost

Effectiveness

ICER

Cost

Effectiveness

ICER

Cost

Effectiveness

ICER

FOBT

$2,295.90

17.041

$13,014.95

$2,295.90

17.041

$13,014.95

$2,295.90

17.041

$13,014.95

FOBT + ASA

$2,673.96

17.094

$7,173.55

$2,673.96

17.094

$7,173.55

$2,673.96

17.094

$7,173.55

Colonoscopy

$2,677.60

17.196

$35.43

$2,677.60

17.196

$35.43

$2,677.60

17.196

$35.43

Colonoscopy + ASA

$3,003.21

17.208

$27,513.64

$3,004.58

17.21

$23,923.52

$3,001.85

17.206

$32,410.73

FOBT/FS

$3,991.03

16.932

(Dominated) ª

$3,991.03

16.932

(Dominated) ª

$3,991.03

16.932

(Dominated) ª

FOBT/FS + ASA

$4,549.99

17.009

(Dominated) ª

$4,549.99

17.009

(Dominated) ª

$4,549.99

17.009

(Dominated) ª

FOBT + COX-2

$62,388.23

17.089

(Dominated) ª

$62,388.23

17.089

(Dominated) ª

$62,388.23

17.089

(Dominated) ª

Colonoscopy + COX-2

$62,810.35

17.207

(Dominated) ª

$62,810.35

17.207

(Dominated) ª

$62,810.35

17.207

80571240.87

FOBT/FS + COX-2

$64,210.65

17.002

(Dominated) ª

$64,210.65

17.002

(Dominated) ª

$64,210.65

17.002

(Dominated)b

FOBT = annual Fecal Occult Blood Test
FOBT/FS - annual Fecal Occult Blood Test and Flexible Sigmoidoscopy every five years
Colonoscopy - Colonoscopy every ten years
ASA - aspirin, 81 milligrams daily
COX-2 - Cyclooxygenase-2 Inhibitor, 425 milligrams daily
ICER = Incremental Cost-Effectiveness Ratio
ªDominated by Colonoscopy plus ASA
Dominated by Colonoscopy plus COX-2

b
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Table 4-17: One Way Sensitivity Analyses Results of Colorectal Cancer Screening Strategies and Chemopreventive Agents
Parameter: pPolyp_Well_Colon_COX2

Base Case:
Screening Strategy

0.123336

Lower Range:

0.114771

Upper Range:

0.131901

Cost

Effectiveness

ICER

Cost

Effectiveness

ICER

Cost

Effectiveness

ICER

FOBT

$2,295.90

17.041

$13,014.95

$2,295.90

17.041

$13,014.95

$2,295.90

17.041

$13,014.95

FOBT + ASA

$2,673.96

17.094

$7,173.55

$2,673.96

17.094

$7,173.55

$2,673.96

17.094

$7,173.55

Colonoscopy

$2,677.60

17.196

$35.43

$2,677.60

17.196

$35.43

$2,677.60

17.196

$35.43

Colonoscopy + ASA

$3,003.21

17.208

$27,513.64

$3,003.21

17.208

$27,513.64

$3,003.21

17.208

$27,513.64

FOBT/FS

$3,991.03

16.932

(Dominated) ª

$3,991.03

16.932

(Dominated) ª

$3,991.03

16.932

(Dominated) ª

FOBT/FS + ASA

$4,549.99

17.009

(Dominated) ª

$4,549.99

17.009

(Dominated) ª

$4,549.99

17.009

(Dominated) ª

FOBT + COX-2

$62,388.23

17.089

(Dominated) ª

$62,388.23

17.089

(Dominated) ª

$62,388.23

17.089

(Dominated) ª

Colonoscopy + COX-2

$62,810.35

17.207

(Dominated) ª

$62,811.60

17.209

80797686.42

$62,809.10

17.205

(Dominated) ª

FOBT/FS + COX-2

$64,210.65

17.002

(Dominated) ª

$64,210.65

17.002

(Dominated)b

$64,210.65

17.002

(Dominated) ª

FOBT = annual Fecal Occult Blood Test
FOBT/FS - annual Fecal Occult Blood Test and Flexible Sigmoidoscopy every five years
Colonoscopy - Colonoscopy every ten years
ASA - aspirin, 81 milligrams daily
COX-2 - Cyclooxygenase-2 Inhibitor, 425 milligrams daily
ICER = Incremental Cost-Effectiveness Ratio
ªDominated by Colonoscopy plus ASA
Dominated by Colonoscopy plus COX-2

b
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Table 4-18: One Way Sensitivity Analyses Results of Colorectal Cancer Screening Strategies and Chemopreventive Agents
Parameter: pCancer_Well_FOBT_ASA

Base Case:
Screening Strategy

Cost

0.00945

Lower Range:

Effectiveness

ICER

Cost

0.008775

Upper Range:

Effectiveness

ICER

Cost

0.010125
Effectiveness

ICER

FOBT

$2,295.90

17.041

$13,014.95

$2,295.90

17.041

$13,014.95

$2,295.90

17.041

$13,014.95

FOBT + aspirin

$2,673.96

17.094

$7,173.55

$2,671.07

17.096

$6,812.88

$2,676.83

17.091

$7,173.55

Colonoscopy

$2,677.60

17.196

$35.43

$2,677.60

17.196

$64.91

$2,677.60

17.196

$35.43

Colonoscopy + aspirin

$3,003.21

17.208

$27,513.64

$3,003.21

17.208

$27,513.64

$3,003.21

17.208

$27,513.64

FOBT/FlexSig

$3,991.03

16.932

(Dominated) ª

$3,991.03

16.932

(Dominated) ª

$3,991.03

16.932

(Dominated) ª

FOBT/FlexSig + aspirin

$4,549.99

17.009

(Dominated) ª

$4,548.17

17.011

(Dominated) ª

$4,551.81

17.007

(Dominated) ª

FOBT + COX-2

$62,388.23

17.089

(Dominated) ª

$62,388.23

17.089

(Dominated) ª

$62,388.23

17.089

(Dominated) ª

Colonoscopy + COX-2

$62,810.35

17.207

(Dominated) ª

$62,810.35

17.207

(Dominated) ª

$62,810.35

17.207

(Dominated) ª

FOBT/FlexSig + COX-2

$64,210.65

17.002

(Dominated) ª

$64,210.65

17.002

(Dominated) ª

$64,210.65

17.002

(Dominated) ª

FOBT = annual Fecal Occult Blood Test
FOBT/FS - annual Fecal Occult Blood Test and Flexible Sigmoidoscopy every five years
Colonoscopy - Colonoscopy every ten years
ASA - aspirin, 81 milligrams daily
COX-2 - Cyclooxygenase-2 Inhibitor, 425 milligrams daily
ICER = Incremental Cost-Effectiveness Ratio
ªDominated by Colonoscopy plus ASA
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Table 4-19: One Way Sensitivity Analyses Results of Colorectal Cancer Screening Strategies and Chemopreventive Agents
Parameter: pCancer_Well_FOBT_COX2

Base Case:
Screening Strategy

0.00972

Lower Range:

0.009045

Upper Range:

0.010395

Cost

Effectiveness

ICER

Cost

Effectiveness

ICER

Cost

Effectiveness

ICER

FOBT

$2,295.90

17.041

$13,014.95

$2,295.90

17.041

$13,014.95

$2,295.90

17.041

$13,014.95

FOBT + ASA

$2,673.96

17.094

$7,173.55

$2,673.96

17.094

$7,173.55

$2,673.96

17.094

$7,173.55

Colonoscopy

$2,677.60

17.196

$35.43

$2,677.60

17.196

$35.43

$2,677.60

17.196

$35.43

Colonoscopy + ASA

$3,003.21

17.208

$27,513.64

$3,003.21

17.208

$27,513.64

$3,003.21

17.208

$27,513.64

FOBT/FS

$3,991.03

16.932

(Dominated) ª

$3,991.03

16.932

(Dominated) ª

$3,991.03

16.932

(Dominated) ª

FOBT/FS + ASA

$4,549.99

17.009

(Dominated) ª

$4,549.99

17.009

(Dominated) ª

$4,549.99

17.009

(Dominated) ª

FOBT + COX-2

$62,388.23

17.089

(Dominated) ª

$62,392.27

17.092

(Dominated) ª

$62,384.18

17.087

(Dominated) ª

Colonoscopy + COX-2

$62,810.35

17.207

(Dominated) ª

$62,810.35

17.207

(Dominated) ª

$62,810.35

17.207

(Dominated) ª

FOBT/FS + COX-2

$64,210.65

17.002

(Dominated) ª

$64,215.15

17.004

(Dominated) ª

$64,206.15

17

(Dominated) ª

FOBT = annual Fecal Occult Blood Test
FOBT/FS - annual Fecal Occult Blood Test and Flexible Sigmoidoscopy every five years
Colonoscopy - Colonoscopy every ten years
ASA - aspirin, 81 milligrams daily
COX-2 - Cyclooxygenase-2 Inhibitor, 425 milligrams daily
ICER = Incremental Cost-Effectiveness Ratio
ªDominated by Colonoscopy plus ASA
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Table 4-20: One Way Sensitivity Analyses Results of Colorectal Cancer Screening Strategies and Chemopreventive Agents
Parameter: pCancer_Well_FOBTFS_ASA

Base Case:
Screening Strategy

0.00672

Lower Range:

0.006214

Upper Range:

0.00717

Cost

Effectiveness

ICER

Cost

Effectiveness

ICER

Cost

Effectiveness

ICER

FOBT

$2,295.90

17.041

$13,014.95

$2,295.90

17.041

$13,014.95

$2,295.90

17.041

$13,014.95

FOBT + ASA

$2,673.96

17.094

$7,173.55

$2,673.96

17.094

$7,173.55

$2,673.96

17.094

$7,173.55

Colonoscopy

$2,677.60

17.196

$35.43

$2,677.60

17.196

$35.43

$2,677.60

17.196

$35.43

Colonoscopy + ASA

$3,003.21

17.208

$27,513.64

$3,003.21

17.208

$27,513.64

$3,003.21

17.208

$27,513.64

FOBT/FS

$3,991.03

16.932

(Dominated) ª

$3,991.03

16.932

(Dominated) ª

$3,991.03

16.932

(Dominated) ª

FOBT/FS + ASA

$4,549.94

17.009

(Dominated) ª

$4,548.99

17.01

(Dominated) ª

$4,550.89

17.008

(Dominated) ª

FOBT + COX-2

$62,388.23

17.089

(Dominated) ª

$62,388.23

17.089

(Dominated) ª

$62,388.23

17.089

(Dominated) ª

Colonoscopy + COX-2

$62,810.35

17.207

(Dominated) ª

$62,810.35

17.207

(Dominated) ª

$62,810.35

17.207

(Dominated) ª

FOBT/FS + COX-2

$64,210.65

17.002

(Dominated) ª

$64,210.65

17.002

(Dominated) ª

$64,210.65

17.002

(Dominated) ª

FOBT = annual Fecal Occult Blood Test
FOBT/FS - annual Fecal Occult Blood Test and Flexible Sigmoidoscopy every five years
Colonoscopy - Colonoscopy every ten years
ASA - aspirin, 81 milligrams daily
COX-2 - Cyclooxygenase-2 Inhibitor, 425 milligrams daily
ICER = Incremental Cost-Effectiveness Ratio
ªDominated by Colonoscopy plus ASA
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Table 4-21: One Way Sensitivity Analyses Results of Colorectal Cancer Screening Strategies and Chemopreventive Agents
Parameter: pCancer_Well_FOBTFS_COX2

Base Case:
Screening Strategy

0.006912

Lower Range:

0.0064052

Upper Range:

0.0073612

Cost

Effectiveness

ICER

Cost

Effectiveness

ICER

Cost

Effectiveness

ICER

FOBT

$2,295.90

17.041

$13,014.95

$2,295.90

17.041

$13,014.95

$2,295.90

17.041

$13,014.95

FOBT + ASA

$2,673.96

17.094

$7,173.55

$2,673.96

17.094

$7,173.55

$2,673.96

17.094

$7,173.55

Colonoscopy

$2,677.60

17.196

$35.43

$2,677.60

17.196

$35.43

$2,677.60

17.196

$35.43

Colonoscopy + ASA

$3,003.21

17.208

$27,513.64

$3,003.21

17.208

$27,513.64

$3,003.21

17.208

$27,513.64

FOBT/FS

$3,991.03

16.932

(Dominated) ª

$3,991.03

16.932

(Dominated) ª

$3,991.03

16.932

(Dominated) ª

FOBT/FS + ASA

$4,549.99

17.009

(Dominated) ª

$4,549.99

17.009

(Dominated) ª

$4,549.99

17.009

(Dominated) ª

FOBT + COX-2

$62,388.23

17.089

(Dominated) ª

$62,388.23

17.089

(Dominated) ª

$62,388.23

17.089

(Dominated) ª

Colonoscopy + COX-2

$62,810.35

17.207

(Dominated) ª

$62,810.35

17.207

(Dominated) ª

$62,810.35

17.207

(Dominated) ª

FOBT/FS + COX-2

$64,210.79

17.002

(Dominated) ª

$64,213.20

17.004

(Dominated) ª

$64,208.39

17.001

(Dominated) ª

FOBT = annual Fecal Occult Blood Test
FOBT/FS - annual Fecal Occult Blood Test and Flexible Sigmoidoscopy every five years
Colonoscopy - Colonoscopy every ten years
ASA - aspirin, 81 milligrams daily
COX-2 - Cyclooxygenase-2 Inhibitor, 425 milligrams daily
ICER = Incremental Cost-Effectiveness Ratio
ªDominated by Colonoscopy plus ASA
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Table 4-22: One Way Sensitivity Analyses Results of Colorectal Cancer Screening Strategies and Chemopreventive Agents
Parameter: pCancer_Well_Colon_ASA

Base Case:
Screening Strategy

0.00336

Lower Range:

0.00312

Upper Range:

0.0036

Cost

Effectiveness

ICER

Cost

Effectiveness

ICER

Cost

Effectiveness

ICER

FOBT

$2,295.90

17.041

$13,014.95

$2,295.90

17.041

$13,014.95

$2,295.90

17.041

$13,014.95

FOBT + ASA

$2,673.96

17.094

$7,173.55

$2,673.96

17.094

$7,173.55

$2,673.96

17.094

$7,173.55

Colonoscopy

$2,677.60

17.196

$35.43

$2,677.60

17.196

$35.43

$2,677.60

17.196

$35.43

Colonoscopy + ASA

$3,003.21

17.208

$27,513.64

$3,002.83

17.209

$26,869.97

$3,003.59

17.208

$28,187.27

FOBT/FS

$3,991.03

16.932

(Dominated) ª

$3,991.03

16.932

(Dominated) ª

$3,991.03

16.932

(Dominated) ª

FOBT/FS + ASA

$4,549.99

17.009

(Dominated) ª

$4,549.99

17.009

(Dominated) ª

$4,549.99

17.009

(Dominated) ª

FOBT + COX-2

$62,388.23

17.089

(Dominated) ª

$62,388.23

17.089

(Dominated) ª

$62,388.23

17.089

(Dominated) ª

Colonoscopy + COX-2

$62,810.35

17.207

(Dominated) ª

$62,810.35

17.207

(Dominated) ª

$62,810.35

17.207

(Dominated) ª

FOBT/FS + COX-2

$64,210.65

17.002

(Dominated) ª

$64,210.65

17.002

(Dominated) ª

$64,210.65

17.002

(Dominated) ª

FOBT = annual Fecal Occult Blood Test
FOBT/FS - annual Fecal Occult Blood Test and Flexible Sigmoidoscopy every five years
Colonoscopy - Colonoscopy every ten years
ASA - aspirin, 81 milligrams daily
COX-2 - Cyclooxygenase-2 Inhibitor, 425 milligrams daily
ICER = Incremental Cost-Effectiveness Ratio
ªDominated by Colonoscopy plus ASA
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Table 4-23: One Way Sensitivity Analyses Results of Colorectal Cancer Screening Strategies and Chemopreventive Agents
Parameter: pCancer_Well_Colon_COX2

Base Case:
Screening Strategy

0.003456

Lower Range:

0.003216

Upper Range:

0.003696

Cost

Effectiveness

ICER

Cost

Effectiveness

ICER

Cost

Effectiveness

ICER

FOBT

$2,295.90

17.041

$13,014.95

$2,295.90

17.041

$13,014.95

$2,295.90

17.041

$13,014.95

FOBT + ASA

$2,673.96

17.094

$7,173.55

$2,673.96

17.094

$7,173.55

$2,673.96

17.094

$7,173.55

Colonoscopy

$2,677.60

17.196

$35.43

$2,677.60

17.196

$35.43

$2,677.60

17.196

$35.43

Colonoscopy + ASA

$3,003.21

17.208

$27,513.64

$3,003.21

17.208

$27,513.64

$3,003.21

17.208

$27,513.64

FOBT/FS

$3,991.03

16.932

(Dominated) ª

$3,991.03

16.932

(Dominated) ª

$3,991.03

16.932

(Dominated) ª

FOBT/FS + ASA

$4,549.99

17.009

(Dominated) ª

$4,549.99

17.009

(Dominated) ª

$4,549.99

17.009

(Dominated) ª

FOBT + COX-2

$62,388.23

17.089

(Dominated) ª

$62,388.23

17.089

(Dominated) ª

$62,388.23

17.089

(Dominated) ª

Colonoscopy + COX-2

$62,810.35

17.207

(Dominated) ª

$62,810.76

17.208

(Dominated) ª

$62,809.95

17.207

(Dominated) ª

FOBT/FS + COX-2

$64,210.65

17.002

(Dominated) ª

$64,210.65

17.002

(Dominated) ª

$64,210.65

17.002

(Dominated) ª

FOBT = annual Fecal Occult Blood Test
FOBT/FS - annual Fecal Occult Blood Test and Flexible Sigmoidoscopy every five years
Colonoscopy - Colonoscopy every ten years
ASA - aspirin, 81 milligrams daily
COX-2 - Cyclooxygenase-2 Inhibitor, 425 milligrams daily
ICER = Incremental Cost-Effectiveness Ratio
ªDominated by Colonoscopy plus ASA

85

5. Discussion and Conclusions
The primary goal of this study was to conduct a cost-effectiveness evaluation of
colorectal cancer (CRC) screening procedures, as well as to determine the usefulness of
aspirin and a cyclooxygenase-2 (COX-2) inhibitor as chemopreventive agents. Since
recommendations for CRC screening vary among professional organizations, and
opinions regarding the screening procedures are even more diverse, the determination of
the most cost-effective screening strategy aids in decision making for both patients and
physicians. This decision involves choosing the strategy that is most effective, least
costly, and best suited for the individual patient. The detailed methodology for
determination of cost-effectiveness of the alternative CRC screening strategies is reported
in Chapter 3. The results of the decision model are presented in Chapter 4. This chapter
discusses the major study findings and their significance. It also includes the major
limitations of the study and presents the significance of the study results. Finally, some
recommendations for future research are also included in this chapter.

5.1 Review of Findings
Cost-effectiveness analysis is an economic evaluation method that can be used to
compare currently recommended screening strategies to aid in informed decision-making.
The incremental cost-effectiveness ratio (ICER) was calculated as the additional cost of a
screening strategy compared to that of the next most cost-effective strategy. The decision
model was developed to determine the costs, effectiveness and ICER of currently
recommended CRC screening strategies in the presence and absence of chemopreventive
agents. The cost-effectiveness analysis was conducted from the societal perspective.
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Results from the analysis showed that the most cost-effective screening strategy
was the use of a fecal occult blood test (FOBT). In terms of only cost, FOBT is the
lowest screening strategy whereas the highest is colonoscopy plus COX-2 inhibitor. This
strategy incurs the highest cost mainly due to the cost of COX-2 ($3,390.24 per year). In
addition, colonoscopy has the highest cost among the three screening procedures. The
most effective strategy is colonoscopy plus aspirin, and FOBT/Flexible Sigmoidoscopy
(FS) was found to be least effective. Colonoscopy plus aspirin has the highest
effectiveness because colonoscopy has the highest effectiveness among the three
screening procedures, as well as the fact that aspirin and COX-2 have an addition benefit
of effectives to the screening procedures. The effectiveness of colonoscopy plus aspirin
(17.2083) and colonoscopy plus COX-2 (17.2072) was very close.
One-way sensitivity analysis was conducted to identify key variables that may
have an impact on the ICERs of the screening strategies. The ICER of the strategies were
sensitive to the costs of FOBT and colonoscopy, as well as the cost of polypectomy. If
the cost of FOBT would be raised slightly ($0.64), or the cost of colonoscopy reduced
slightly ($3.80), the ICER would be affected so that the strategy FOBT plus aspirin
would become dominated by colonoscopy. This domination occurs because the cost of
colonoscopy now becomes lower than the cost of FOBT plus aspirin, while the
effectiveness remains higher. Additionally, if the cost of polypectomy increased by
approximately $30.00, FOBT plus aspirin would again become dominated by
colonoscopy. Again, this means the cost of colonoscopy now becomes lower than the
cost of FOBT plus aspirin, while the effectiveness remains higher. The ICER of FOBT
plus aspirin and colonoscopy were also quite sensitive to the cost of aspirin. Aspirin has

87

a base case cost of $18.00 per year, and if this cost were increased to $18.21, FOBT plus
aspirin would become dominated by colonoscopy yet again. However, the ICERs were
not sensitive to the cost of COX-2 inhibitor.
This study is among the first to employ a decision analysis model to evaluate the
most commonly utilized screening procedures (FOBT, FS, and colonoscopy), along with
the addition of aspirin and COX-2 inhibitor as chemopreventive agents. Four previous
studies have evaluated the cost-effectiveness of the three screening procedures used in
this study (Wagner and colleagues, 1996,; Frazier and colleagues, 2000; Khandker and
colleagues, 2000; Vijan and colleagues, 2001). Each of these studies measured outcomes
in cost per life years saved. This study uses the measure of quality adjusted life years
(QALYs). Vijan and colleagues (Vijan, et al., 2001) concluded that FOBT was the most
cost-effective screening strategies, followed by colonoscopy, FS, and lastly FOBT/FS.
The results of the Wagner study (Wagner, et al., 1996) were similar, except colonoscopy
was more cost-effective than FOBT. Frazer (Frazier, et al., 2000) and Khandker
(Khandker, at al., 2000) both concluded that FS was the most cost-effective, followed by
FOBT. However, the difference between these two studies is that colonoscopy was more
cost-effective than FOBT/FS in the Frazier study, while Khandker found the combination
strategy to be more cost-effective than colonoscopy.
The screening strategies of FOBT, FOBT plus aspirin, colonoscopy, and
colonoscopy plus aspirin all have an ICER of less than $50,000 per QALY. In health
economics, a figure of $50,000 per QALY is often suggested as the upper limit of an
acceptable ICER. No previous decision analysis study has evaluated both aspirin and
COX-2 inhibitor as chemopreventive agents.
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5.2 Implications of Study Findings
The study results will be a valuable addition to the scientific literature in the field
of CRC screening. In addition to its academic importance, the study results have
implications for decision makers of CRC screening; physicians, administrators, and
patients.
The results from the study suggest that FOBT, FOBT plus aspirin, colonoscopy,
and colonoscopy plus aspirin are the more cost-effective of all the screening strategies
employed. FOBT plus aspirin and colonoscopy have similar cost-effectiveness with
colonoscopy having an ICER of only $35.43. This is due to both strategies being quite
sensitive to the cost of FOBT and colonoscopy.

5.3 Study Limitations
This study has limitations which are noted below. These limitations need to be
considered when deriving inferences from the reported results.

1. A decision model for economic evaluations is only as good as the data that is used
to populate the model. The impact of uncertainty in the parameter estimates on
the results was evaluated by conducting a sensitivity analysis.
2. The base case analysis assumes that the study population used for parameter
estimates are comparable in their demographic and clinical characteristics. In
reality, this is possibly only through randomization of the cohort to each screening
strategy included in the model.
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3. In this study, we assumed 100% compliance for screening. Vijan and colleagues
(2001) report that colonoscopy at ages 50 and 60 years is the preferred test
regardless of compliance with the primary screening test. However, if follow-up
colonoscopy for polyps is less than 75%, then even once-lifetime colonoscopy is
preferred over most combinations of flexible sigmoidoscopy (FS) and FOBT.
This may suggest that compliance regarding recommended screening intervals
does not directly affect the effectiveness of the screening strategy.

4. In this model, the treatment rate was set at 100%. That is, everyone who is
diagnosed with CRC would be treated. Although this is not true in clinical
practice, a specific rate could not be otherwise found to estimate this. Therefore,
the 100% rate was used to estimate treatment.

5. The screening procedures of FOBT and FS were modeled together as a combined
strategy. The strategy was modeled after the study by Winawer and colleagues
(1997). This strategy involves an annual FOBT with a FS every five years. The
fifth year screening estimate is not a combined probability of FOBT and FS. If on
the fifth year the FOBT returns a positive test, the FS is foregone and a diagnostic
colonoscopy is performs.
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5.4 Recommendations for Future Research
As mentioned previously, an economic model is only as good as the data used to
develop it. The model should be populated with estimates of effectiveness and costs of
each screening procedure and chemopreventive agents from their use in clinical practice.
Future research should be targeted at developing a decision model that incorporates
compliance with screening procedures. Additionally, the probability of treatment should
be taken into consideration in the model.
This study incorporated screening procedures which are most common in current
practice. As newer technologies emerge, and screening guidelines are revised, future
studies should incorporate these factors to assess their cost-effectiveness.

5.5 Conclusions
In this study, fecal occult blood test (FOBT) and colonoscopy were the most costeffective screening procedures in this study. The strategies that incorporated these
procedures, along with the addition of aspirin, were the four dominant strategies in this
study. The combination strategies of FOBT/FS was the least cost-effective of the
procedures, regardless of the addition of chemopreventive agents. Strategies that
incorporated a Cox-2 inhibitor as the chemopreventive agent were the least cost-effective
due to the prohibitive cost of the drug. It did, however, prove to increase the
effectiveness of screening procedures. If the cost of Cox-2 inhibitors were lower, these
screening strategies would become more competitive with those that incorporate aspirin
as the chemopreventive agent. However, until then, aspirin remains as the most costeffective chemopreventive addition to CRC screening procedures.
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